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A549: Human lung carcinoma cell line 
ACN: Acetonitrile 
ACPP: Active cell penetrating peptide 
ADC: Antibody-drug conjugate 
ADCC: Antibody-dependent cellular 
cytotoxicity 
AKt/PKB: Protein kinase B 
Ala: Alanine 
ALL: Acute lymphoblastic leukemia 
AMAS: N-(α-maleimidoacetoxy) succinimide 
ester 
AML: Acute myeloid leukemia  
APN: Aminopeptidase N 
aq.: Aqueous solution 
Bn: Benzyl 
Boc: tert-Butyloxycarbonyl 
CAIX: Carbonic anhydrase IX 
CCRF-CEM: human leukemic lymphoblasts  
CDC: Complement dependent cytotoxicity 
Cit: Citrulline 
CPT: Camptothecin 
CuAAC: Copper (I) catalyzed alkyne-azide 
cycloaddition 
DAR: Drug-antibody ratio 










DMSO: Dimethyl sulfoxide 





ECM: Extracellular matrix 
EDC: N-(3-Dimethylaminopropyl)-Nʹ-
ethylcarbodiimide hydrochloride 
EDT: ethanedithiol  
EEDQ: N-Ethoxycarbonyl-2-ethoxy-1,2-
dihydroquinoline 
EGFR: Epithelial growth factor receptor 
Ep-CAM: Epithelial cell adhesion molecule 
eq.: equivalents 
ESI Electrospray ionization 
EtOAc: Ethyl acetate 
FACS: Fluorescence-activated cell sorting  
FAK: Focal adhesion kinases 
FDA: US Food and Drug Administration 
FL: Follicular lymphoma  
Fmoc: 9-Fluorenylmethoxycarbonyl 
FN: Fibronectin 
FR: Folate receptor 
GI: Gastrointestinal 
GM: Glioblastoma multiforme 




HPLC: High performance liquid 
chromatography 
HT29: Human colon cancer 
HUVEC: Human umbilical endothelial cells 
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IC50: Maximum half inhibitory concentration 
ICAM 1: (Intercellular Adhesion Molecule 1 
IgG: Immunoglobulin G 
IL-8: Interleukin 8 
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isoDGR: isoAspartic-Glycine-Arginine 
LNCaP: androgen-sensitive human prostate 
 adenocarcinoma cell line 
LRP1: Low-density lipoprotein 
LTT: Ligand-targeted therapeutics 
mAb: Monoclonal antibody 
MS: Mass spectroscopy 
mCRC: metastatic colorectal cancer 
MCRPC: Metastatic castration-resistant 
prostate cancer 
MDA-MB-468: Human breast cancer cell 
line 
MED: Minimum effective dose 
MeOH: Methanol 
MIDAS: Metal ion-dependent adhesion site 
MMAE: Monomethyl auristatin E 
MMAF: Monomethyl auristatin F 
MMP: Matrix metalloproteinase  
MTD: Maximum tolerated dose 
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NHS: N-Hydroxysuccinimide 
NMR: Nuclear Magnetic Resonance 
NSCLC: Non-small-cell lung cancer 
OATP: organic anion transporting 
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PABA: p-aminobenzyl alcohol 
PABC: p-aminobenzyl carbamate 
PaCa2: human pancreatic duct 
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PEG: Polyethylene glycol 
pHLIP: pH low insertion peptides  
PNP: p-nitrophenyl chloroformate 
PSMA: Prostate specific membrane antigen  
PTX: Paclitaxel 
RGD: Arginine-Glycine-Aspartic 
rt.: room temperature  
SCLC: Small-cell lung cancer 
SIP: Small immune proteins 
SMDC: Small molecule-drug conjugate 
SPDP: N-Succinimidyl 3-(2-pyridyldithio) 
propionate 
SSTR: Somatostatin receptor 
sulfo-Lc-SMPT : sulfosuccinimidyl 6-[α-
methyl-α-(2-pyridyldithio)toluamido] 
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THF: Tetrahydrofuran 
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Project overview  
 
The lack of selectivity is one of the main limitations of traditional chemotherapy 
because of the severe side effects associated to high drug dosages. Targeted drug 
delivery is therefore a growing-interest field in cancer therapy as a strategy for 
overcoming the systemic cytotoxicity. This approach is inspired by the “magic-bullet” 
concept of Paul Ehrlich, awarded with the Medicine Nobel Prize in 1908 for his work in 
immunotherapy, concept applied to cancer therapy nowadays to propose the use of 
drug-delivery vehicles (monoclonal antibodies, peptides, nanoparticles, polymers) 
targeting a specific antigen or receptor to liberate the payload at the tumor site without 
affecting the healthy tissue.  
The antibody-drug conjugates (ADCs) and the small molecule-drug conjugates (SMDC) 
belong to this new generation of therapeutics. In ADCs, the targeting agent is a 
monoclonal antibody (mAb) while in SMDCs the targeting is performed by a low 
molecular weight ligand (peptide, vitamin or peptidomimetic). In both cases the 
targeting moiety is connected to a potent warhead by means of a stable linker and they 
are expected to efficiently deliver the cytotoxic agent to the tumor cells preferentially 
via receptor-mediated endocytosis. Currently, four ADCs: Mylotarg, Kadcyla, Adcetris 
and Besponsa, have been approved by the US FDA for the treatment of different 
cancers. Despite this success, ACDs present some drawbacks related to the use of mAbs 
such as high manufacturing costs, unfavorable pharmacokinetics (low tissue diffusion 
and low accumulation rate) and possible immune response, for this reason smaller 
formats like SMDCs have become an interesting alternative for the selective delivery of 
drugs into tumors.   
Our research group has developed during the last decade a number of cyclic 
peptidomimetic ligands containing the tripeptide RGD or isoDGR sequences and the 
bifunctional diketopiperazine (DKP) scaffold. These ligands are recognized by the 





cancers (e.g. breast cancer, glioblastoma, pancreatic tumor, prostate carcinoma) but 
not on the vasculature of healthy tissues, constituting a suitable therapeutic target. In 
particular, the cyclo[DKP-isoDGR] integrin ligand has shown not only a high binding 
affinity and selectivity for the purified receptor αVβ3 but also an integrin antagonist 
activity, becoming a promising ligand for the preparation of SMDCs. 
This PhD thesis describes the synthesis and biological evaluation of SMDCs containing 
the functionalized cyclo[DKP-isoDGR] integrin ligand and potent cytotoxic drugs (α-
amanitin, MMAE and MMAF) combined via different linkers and spacers. The purpose 
of this project is to study the efficacy of the cyclo[DKP-isoDGR] integrin ligand 
developed by our research group as a vector for targeted drug delivery. The work is 
divided in three chapters: the Chapter 1 introduces the definition of SMDC as part of 
the new targeted therapies strategies; the Chapter 2 presents the characteristics of the 
integrin receptors family, previous work on targeted drug-delivery via integrin ligands 
and the synthesis of the functionalized cyclo[DKP-isoDGR] integrin ligand; and the 
Chapter 3 presents the synthesis of the SMDCs containing the cyclo[DKP-isoDGR] 
integrin ligand and different cytotoxic agents, along with the discussion of the in vitro 
results, including binding affinity tests towards the isolated αVβ3 integrin receptor and 
antiproliferative activity assays in cancer cell lines with different levels of αVβ3 
expression.  
Finally, the experimental procedures and in vitro test protocols are detailed in the 








Chapter 1. Targeted drug delivery for tumor therapy 
 
1.1. Targeted cancer therapies 
Cancer has a major impact on society as it represents one of the main causes of death 
worldwide. Statistics from the World Health Organization indicate that 8.8 million 
people died of cancer in 2015 and, approximately 1 in 6 deaths globally is related to this 
desease.1 
Among the anticancer therapies developed during the last decades, chemotherapy 
remains the most employed together with radiation therapy and surgery. Traditional 
chemotherapy uses low-molecular weight drugs (Figure 1) that modify or interrupt the 
cell cycle at different stages.2,3 These cytotoxic drugs can be classified by their 
mechanism of action in: 
- Antimetabolites 
These drugs can alter essential biological pathways by mimic nitrogenous bases or 
inhibiting enzymes involved in the synthesis of nucleic acids. 5-Fluoracil (5-FU) and 
6-mercaptopurine (6-MP), analogues of pyrimidine and purine respectively, are 
examples of antimetabolite drugs. The incorporation of these analogues during the 
phase S of cell cycle interrupts the replication of DNA and leads to apoptosis. 
Another example of this group is methotrexate, an antifolate that blocks the 
synthesis of nucleotides by inhibition of the dihydrofolate reductase.4 
- DNA damaging agents 
- Alkylating agents: They act by alkylating DNA on purine bases blocking replication. 
Nitrogen mustards derivatives (e.g. cyclophosphamide, chlorambucil, melphalan); 





temozolomide) and natural products like mitomycin C and streptozotocin belong to 
this group.4,5 
- Cross-linking agents: Some alkylating agents can also bind DNA causing inter-strand 
crosslink (DNA crosslink on opposite strands of the double helix), with subsequent 
double toxic effect in cells.  Platinum complexes and derivates (e.g. cisplatin, 
carboplatin, oxaliplatin) can form intra-strand crosslinks when forming adducts with 
adjacent bases on the same DNA strand. Both inter-strand and intra-strand 
crosslinks lead to apoptosis by interruption of DNA replication.5 
- Intercalating agents: Bind between base pairs of nucleic acids preventing 
replication. Examples of this group of drugs are the anthracyclines doxorubicin, 
daunorubicin, epirubicin, mitoxantrone and antinomycin-D.4,5 
- Toposisomerase poisons: Topoisomerases are enzymes responsible for the 
cleavage, annealing and topological state of DNA double helix. Toposisomerase I 
inhibitors (e.g. camptothecin, irinotecan, topotecan) and toposisomerase II 
inhibitors (etoposide, anthracyclines) trap the DNA-enzyme complex inhibiting 
replication fork progression.6 
- Antitubulin agents 
Tubulin is a globular protein that plays an essential role in cellular replication. 
Antitubulin agents, also known as mitotic inhibitors, alter the microtubule 
polymerization dynamics (coexistence of tubulin assembly and disassembly) blocking 
the division of the nucleus and leading cell to apoptosis. There exist two groups of 
antitubulin agents: microtubules stabilizers (e.g. Paclitaxel, docetaxel, epothilones) and 






Figure 1. Molecular structures and use of common anticancer drugs8 
The cytotoxic agents described above are expected to attack preferentially the tumor 
cells, as these undergo much more rapid proliferation than normal cells. Unfortunately, 
these drugs can also kill normal dividing cells in the body (e.g. hair, bone marrow, 
gastrointestinal track) and accumulate in other organs rather than tumor area (Figure 
2), displaying severe side effects. Due to the systemic cytotoxicity, the administrated 
dose is often reduced to suboptimal level with poor benefit for the patient.3,9,10 
 
Figure 2. Biodistribution of 11C-docetaxel in male patient with metastatic malignant pleural 
mesothelioma. PET scans at different time points (0–6, 8–19, 23–39 and 42–63 min) display low drug 
uptake in the affected region (pleural mesothelium) but high accumulation in the liver and intestine. 
Adapted with permission from A.A.M. van der Veldt, N.H. Hendrikse, E.F. Smit et al. Eur. J. Nucl. Med. 





With the purpose of improving the therapeutic index (maximum tolerated 
dose/minimum effective dose) of anticancer drugs, modern strategies are oriented 
towards targeted therapies. These are based on the concept of “magic-bullet”, 
envisaged by Paul Ehrlich (Medicine Nobel Prize, 1908) who coined the term referring 
to a therapeutic agent that could attack the bacteria responsible of diseases without 
hurting the host.12  
 
Figure 3. Targeted chemotherapy approach. Adapted with permission from Siler Panowski, Sunil Bhakta, 
Helga Raab, Paul Polakis and Jagath R. Junutula; mAbs, 2014, 6 (1), 34-45. Copyright © 2014 Landes 
Bioscience 
Nowadays, targeted cancer therapies aim at selectively killing cancer cells by interfering 
with essential pathways involved in tumor growth (e.g. signal-transduction pathways) or 
by efficiently delivering the cytotoxic agents to the tumor without compromising the 
healthy cells. Most common targets are molecular markers or antigens that play an 
important role in cell proliferation (e.g. cell surface proteins, glycoproteins, or 
carbohydrates) and that are over-expressed in tumor cells compared with normal 
tissues.3,13  
Three main approaches can be identified in this field: small molecules tyrosine kinase 
inhibitors designed to prevent the activation of signaling pathways dysregulated in 
tumor cells (e.g. imatinib – Gleevec®, sunitinib)14–16; monoclonal antibodies (mAbs) 
targeting specific antigens displayed in tumor cells; and ligand-targeted therapeutics 
(LTT) where a drug-delivery vehicle (e.g. monoclonal antibody, small ligand, peptide, 
nanoparticle, polymer) is used to target specific antigens or receptors and liberate the 





drug conjugates (SMDCs) belong to this last category and will be described in the next 
sections. 
1.2. Monoclonal antibodies  
Antibodies, also known as immunoglobulins (Ig), are a group of glycoproteins produced 
by the immune system that detect and selectively bind antigens displayed in abnormal 
cells, prompting an immune attack that destroys the cell expressing the antigen.19 In 
1975, Köhler and Milstein developed the hybridoma technology,20 where antibodies 
produced by B lymphocytes of mice were isolated and fused with immortal myeloma 
cell lines to obtain clonal cells known as hybridomas. Hybridomas can be cultured to 
produce large amounts of identical antibodies specific for an antigen, these are called 
monoclonal antibodies (mAbs). 
 
Figure 4. Structure and classification of monoclonal antibodies (mAbs).21 Fab: fragment antigen-binding; 
Fc: fragment crystallizable; CDR: complementary determining region; A) murine antibody; B) Chimeric 
antibody: murine variable regions and human constant regions; C) Humanized antibody: human variable 
and constant region, murine CDRs; D) Fully human antibody. Adapted with permission from K. R. 
Rodgers and R. C. Chou. Biotechnol. Adv. 2016, 34 (6), 1149–1158. Copyright © 2016 Elsevier Inc. 
The therapeutic potential of mouse mAbs (Figure 4A) was restricted by the response of 
patients’ immune system, which recognized the antibodies as foreign entities and 
generated human anti-mouse antibodies (HAMA), resulting in rapid clearance of the 
mAb from circulation. Further advances in recombinant DNA technology led to the 
production of chimeric mAbs (Figure 4B) where the constant regions of the murine 
antibody were replaced by human constant regions sequences, retaining the murine 
variable domains responsible for antigen binding. Later, it was also possible to replace 
the variable sequences of mouse mAbs with human sequences to obtain humanized 





and the use of transgenic mice have made possible the generation of fully human mAbs, 
significantly reducing the immune response reported for the first mAbs.3,21,22 
The antitumoral activity of monoclonal antibodies can be attributed to different cell-
killing mechanisms.23 Among them we can summarize:  
- Direct action of the antibody: by binding the targeted receptor and displaying an 
antagonist activity, blocking the dimerization, kinase activation and downstream 
signaling, inhibiting proliferation and inducing apoptosis. 
- Immune-mediated cell killing: induction of phagocytosis, complement dependent 
cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) or regulation of 
T-cell function. 
- Effect of the antibody on tumor vasculature and stroma: vasculature receptor 
antagonism, stromal cell inhibition. 
These mechanisms have been validated in the clinic, leading to the approval of more 
than 24 mAbs targeting 16 different antigens, that are currently available in the market 
for the treatment of an increasing number of cancers.24 Some examples include the 
chimeric mAb Rituximab (the first mAb approved by the FDA for cancer treatment in 
1997), that binds the CD20 antigen expressed on the surface of B cells, indicated for the 
treatment of follicular lymphoma (FL) and low-grade non-Hodgkin’s lymphoma (NHL);25 
Alemtuzumab, a humanized mAb that targets CD52 antigen overexpressed on 
malignant lymphocytes, approved for therapy of resistant lymphocytic leukemia;26 
Bevacizumab, another humanized mAb that binds to the vascular endothelial growth 
factor receptor (VEGF) on cancer cells, inhibiting the formation and growth of tumor 
blood vessels, used in the treatment of metastatic colon and kidney cancer, non-small 
cell lung cancer and glioblastoma;27 the human mAb panitumumab, indicated for the 
treatment of metastatic colorectal cancer (mCRC) expressing the epithelial growth 
factor receptor (EGFR);28 and the humanized mAb trastuzumab (Herceptin®), that 
targets the human epidermal growth factor receptor 2 (HER2) overexpressed in 20-30% 






1.3. Antibody-drug conjugates (ADC) 
The high specificity of monoclonal antibodies and the positive results obtained from the 
combination of mAbs with chemotherapy led to the idea of developing new conjugated 
entities where the mAbs were covalently bound to cytotoxic drugs. The so-called 
antibody-drug conjugates (ADCs) consist of a monoclonal antibody connected to a 
potent cytotoxic drug via a chemically stable linker to prevent the premature release of 
the payload in the blood circulation. Ideally, an ADC should liberate the cytotoxic agent 
at the tumor site after selectively binding its target, expressed on tumor cells surface, 
leaving the healthy cells unharmed.13,31  
The first generation of ADCs, based on chimeric or humanized mAbs and regular-
potency cytotoxic payloads (e.g. doxorubicin, methotrexate), faced several problems in 
clinical trials because of immunogenicity, limited potency and insufficient selectivity.32 
Learning from the early results, scientists optimized the ADCs design by selecting more 
specific targets, replacing chimeric mAbs by humanized or fully human mAbs to prevent 
immunogenicity, and using ultra-potent cytotoxic drugs (100-1000 times more potent). 
The drug-antibody ratio (DAR) in the second-generation ADCs is around 4:1, resulting in 
more efficient cytotoxicity.33,34 Currently, a new generation of ADCs is being developed 
with the incorporation of bispecific antibodies and site-specific conjugation of the drug 
that allows a better control of the DAR.35 
At present, four ADCs have received FDA approval and more than 60 are being 
evaluated at different stages of clinical trials (Figure 5). The first ADC commercialized 
was gemtuzumab ozogamicin (Mylotarg®, Wyeth-Pfizer), a first-generation ADC 
approved in 2000 for the treatment of CD33-positive acute myeloid leukemia (AML). It 
was voluntarily withdrawn from the US market in June 2010 and reintroduced in 
September 2017. The other three are second-generation ADCs: brentuximab vedotin 
(Adcetris®, Seattle Genetics) approved in 2011 for the treatment of anaplastic large cell 
lymphoma and Hodgkin lymphoma; ado-trastuzumab emtansine (Kadcyla®, Genentech), 
approved in 2013 for the treatment of HER2-positive breast cancer and  inotuzumab 
ozogamicin (Besponsa®, Pfizer) approved in 2017 for the treatment of adults with 






Figure 5. Structure and classification of three ADCs approved by FDA.35 A) The first-generation ADC 
gemtuzumab ozogamicin (Mylotarg®) contains a humanized mAb (IgG4) specific for CD33 antigen 
conjugated to 2–3 calicheamicin moieties which are attached via cleavable hydrazone linkers to random 
lysine residues; B) The second-generation ADC trastuzumab emtansine (Kadcyla ®) contains a humanized 
mAb (IgG1) specific for human epidermal growth factor receptor 2 (HER2) and 3–4 DM1 moieties 
attached via non-cleavable thioether linkers to random lysine residues; C) The second-generation ADC 
brentuximab vedotin (Adcetris®) contains a chimeric mAb (IgG1) specific for CD30 antigen and 4 
monomethyl auristatin E (MMAE) moieties attached to the hinge region through a protease-cleavable 
Val-Cit linker. Adapted with permission from A. Beck; L. Goetsch; C. Dumontet; N. Corvaïa. Nat. Rev. 
Drug Discov. 2017, 16 (5), 315–337. Copyright © 2016 Elsevier Inc. 
1.3.1. Design and mechanism of action of ADCs 
Among the factors to consider for the development of efficient ADCs, the most 
determinant are the choice of the target, the binding affinity and immunogenicity of the 
antibody, the nature of the linker and the potency of the cytotoxic drug.31 Most ADCs 
are designed to kill cancer cells in a target-dependent mechanism that involves the 
internalization of the ADC via a receptor-mediated endocytosis pathway (Figure 6).37,38  
The first step in this process is the binding of the antibody to its antigen, localized 
preferentially on the cell surface of tumor cells. Once the ADC-antigen complex is 
formed, it is internalized into endosomes that subsequently mature and fuse with 
lysosomes. In the lysosomes, the drug is released via cleavage of the linker by specific 
proteases such as cathepsin B or by degradation of the ADC, then the free drug reaches 
its target in cytoplasm leading to cell death. The cell-killing mechanism depends of the 
class of cytotoxic drug used (e.g. tubulin polymerization inhibition by maytansines and 





cells can also be killed when the free drug crosses the plasma membrane and access the 
extracellular environment in a process known as the bystander killing effect.39,40 
 
Figure 6. Design of ADCs and cell-killing mechanism. A) General structure of ADCs and factors to be 
consider for the design. B) Receptor-mediated endocytosis pathway: 1) the antibody moiety binds to its 
cell-surface antigen receptor target and form an ADC-antigen complex; 2) the complex is internalized 
into endosome that fuse with lysosomes; 3) the internalized complex undergoes lysosomal processing; 
4) the cytotoxic payload is released inside the cytosol; 5) the payload reaches its target leading to cell 
death. Adapted with permission from Siler Panowski, Sunil Bhakta, Helga Raab, Paul Polakis and Jagath 
R. Junutula; mAbs, 2014, 6 (1), 34-45. Copyright © 2014 Landes Bioscience 
Recent approaches in the design of ADCs have questioned the internalization 
requirement for ADC efficiency. In effect, potent activity in tumor preclinical models has 
been reported for non-internalizing ADCs directed against splice isoforms of fibronectin 
and tenascin-C, both  expressed on the extracellular matrix of tumor blood vessels.41–43 
In this case, the release of the cytotoxic drug is triggered by the glutathione or 
proteases present in the extracellular space upon tumor cell death, followed by the 
passive diffusion of the drug, which should be lipophilic enough to guarantee a 
homogeneous drug delivery to the tumor. 
1.3.2. Limitations of ADCs 
Despite the successful approval of four ADCs and the remarkable progress achieved in 
this field, there remain some limitations concerning the immunogenicity of the 
antibody, the stability of the linker, the antigen targeting and the heterogeneity of the 
antigen expression in the tumor.44,45 Specifically, in the case of solid tumors, the 





contrary to hematologic tumors, the targets are overexpressed in a small portion of the 
patient populations (e.g. only 20% of breast cancer express HER2 and is eligible for the 
treatment with Kadcyla). Also, due to its large size antibodies do not extravasate and 
diffuse efficiently into tissue, once they reach the blood vessels they are trapped by the 
antigens located on perivascular tumor cells, preventing the targeting on the integrity of 
the tumor area. This is known as the “antigen-barrier” effect.9,46 
 
Figure 7. Various sizes antibody formats and alternative scaffolds for drug delivery.47 A) Engineered 
antibody formats: (a) Immunoglobulin-G, (b) Small immune protein SIP, (c) diabody, (d) Fab fragment, 
(e) single chain Fv (scFv), (f) domain antibody (dAb); B) Protein scaffolds: (g) Designed ankyrin repeat 
protein (DARPin), (h) Adnectin,(monobody) (i) affibody, (j) knottin peptide, (k) bicyclic peptide. Adapted 
with permission from M. Deonarain; G. Yahioglu; I. Stamati et al. Antibodies 2018, 7 (2), 16. 
Current strategies in ADC technology seek to overcome the pharmacokinetic limitations 
by using smaller formats such as antibody fragments, diabodies, mini-antibodies or 
small immune proteins (SIP) (Figure 7). Even though immunoglobulins (IgG) have a 
longer circulation half-life that allows maximal accumulation at the tumor site, recent 
studies support the concept that smaller formats have higher diffusion and 
extravasation coefficients, hence they can penetrate better the solid tumors.48,49 Lower 
plasma exposure also reduces the risk of premature release of the payload and the lack 
of a Fc domain in mAb fragments can minimize cross-reactivity with Fc-receptors on 





1.4. Small molecule-drug conjugates (SMDCs) 
The search for smaller vehicles for targeted drug delivery generated a new class of 
ligand-targeted cytotoxic agents where the targeting moiety is a low-molecular weight 
ligand (e.g. peptide, vitamin, peptidomimetic) with potentially favorable 
pharmacokinetic properties and that can be easily accessed by chemical synthesis. The 
so called small-molecule drug conjugates (SMDC) are similar to ADCs in structure and 
mechanism of action. They contain a linker system that connects the ligand to the 
cytotoxic drug and are expected to deliver the payload at its intracellular target in the 
tumor by receptor-mediated endocytosis (Figure 8). The considerations for the design 
of efficient ADCs are also valid for the SMDCs, being most determinant the choice of the 
target, the ligand, the nature of the linker and the potency of the payload.9,18,50  
 
Figure 8. General structure and mechanism of action of SMDCs. A) General structure of SMDCs. B) 
Receptor-mediated endocytosis pathway: (a) the targeting moiety binds to its cell-surface receptor 
target and form a SMDC-receptor complex; (b) the complex is internalized into endosomes that fuse 
with lysosomes; (c) the internalized complex undergoes lysosomal processing; the linker is cleaved and 
the cytotoxic drug is released to reaches its intracellular target; (d) the receptor is recycled to cell 
surface. Adapted from https://endocyte.com/. 
1.4.1. Target selection 
One of the most important aspects for the choice of a suitable target is the receptor 
expression profile. This includes the expression of the targeted receptor in tumor cells 
vs normal tissues and the absolute level of receptor’s isoforms expression in tumor 
cells. Ideally, the targeted receptor must be sufficiently overexpressed in tumor cells 
compared to normal to avoid off-target cytotoxicity; some studies have stablished as 
acceptable a 3-fold or higher magnitude of receptor overexpression in cancer cells.51,52 





receptors per cancer cell53 and the prostate-specific membrane antigen (PSMA) is 
expressed in 1 million excess by LNCaP prostate cancer cell line54. Other receptors 
overexpressed in a variety of cancer cells are the somatostatin receptor 2 (SSTR2), the 
sigma non-opioid intracellular receptor (SIGMAR1 and 2), cell-adhesion proteins ICAM1, 
LFA1 and CD24 and certain integrins.9,13 
Most targeted receptors are expressed on the surface of cancer cells, allowing a better 
accessibility for the targeting ligand. In general, once the ligand binds the cell-surface 
receptor, forms the SMDC-receptor complex that is internalized via endocytosis to an 
intracellular compartment (recycling endosome or a lysosome) where the complex is 
dissociated, allowing the receptor to be either degraded or recycled to the cell surface 
(Figure 8B). As the availability of empty receptors on the targeted tumor cell depends 
on the rate of return of unoccupied receptors, an ideal receptor will be frequently 
recycled or resynthesized following degradation.9,50  
1.4.2. Choice of the ligand  
The binding affinity and specificity of the small ligand for the targeted receptor are basic 
for the optimal performance of SMDCs. A high binding affinity allowing the access to the 
targeted receptor and rapid extravasation, can increase the accumulation ratio 
tumor:blood, tumor:organ of the drug, avoiding the fast clearance often associated to 
the use of small molecules.13,18 The specificity is also very important, especially when 
there are other members of the receptor family that can be recognized by the ligand, 
compromising the tumor targeting. Some of the ligands currently used in SMDCs 
include PSMA ligands,50,55 folic acid analogues56 and carbonic anhydrase IX (CAIX) 






Figure 9. Small ligands targeting PSMA, folate receptor and CAIX 
 
Another important aspect is the derivatizability of the ligand. In order to be conjugated 
to the linker (or to the connecting spacer) the targeting ligand should preferably have a 
derivatizable functional group (e.g. carboxylic acid, amine, alcohol, thiol) that enable the 
coupling to further entities via simple chemistry (e.g. formation of amides, carbamates, 
oximes, esters, carbonates or disulphides). One advantage of the use of small molecule 
ligands is that they can be prepared by chemical synthesis and optimized through 
structure-activity relationship (SAR) studies to identify the sites where modification will 
not interfere with receptor binding.50,59 
1.4.3. Linker design 
The design of the linker system is a key factor in the optimization of the SMDCs because 
it has direct influence in the pharmacokinetic profile. As most SMDCs are designed to be 
cleaved or degraded intracellularly, the linker should be stable at physiological 
conditions but assure an efficient release of the payload after receptor-mediated 
internalization. In general, linkers can be divided in: 
- Acid-sensitive linkers: functional groups (e.g. esters or hydrazone) that remain 
stable in blood circulation (pH 7.5) and get hydrolyzed in acidic tumor micro-
environment (lysosomal pH 4.8 and endosomal pH 5–6). The hydrazone linker has 





This linker is applicable for conjugating drugs or their derivatives containing a 
chemical moiety (e.g. ketone or aldehyde) that can be coupled to a hydrazine-
terminated linker (Figure 10).66 
 
Figure 10. Structures of hydrazone-based linker types as applied for doxorubicin conjugation: (a) acyl 
hydrazone, (b) alkoxycarbonyl hydrazone, (c) sulfonyl hydrazone. Doxorubicin release occurs primarily in 
acidic compartments such as endosomes and lysosomes as a result of acid-catalyzed hydrolysis of the 
hydrazone linker. Adapted with permission from P. T. Wong and S. K. Choi; Chem. Rev. 2015, 115, 3388-
3432. Copyright © 2015 American Chemical Society. 
- Disulfide linkers: disulfide bonds can be reduced inside cytoplasm by endogenous 
thiol molecules (e.g. cysteine, glutathione). Glutathione is a low molecular weight 
thiol present in the cytoplasm (0.5–10 mM) and the extracellular environment in 
minor scale (2–20 µM in plasma). Tumor cells present elevated levels of glutathione 
(10-20 mM) due to stress conditions such as hypoxia.67,68 This higher expression 








Figure 11. Mechanism of drug release of self-immolative disulfide linkers. (a) when reduced by 
glutathione, a self-immolative cleavage of the disulfide bond leads to release of a free drug with the 
formation of stable byproducts (a) CO2 + a thiirane, (b) CO2 + thiolactone, (c) CO2 + thioquinone 
methide. GSH = glutathione; X = O or NH. Adapted with permission from: M. Srinivasarao and P. S. Low; 
Chem. Rev.  2017, 117, 12133-12164. Copyright © 2017 American Chemical Society 
- Enzymatically-cleavable linkers: these linkers are generally constituted by short 
peptide sequences (e.g. Val-Ala, Val-Cit) designed to be cleaved by enzymes 
upregulated or activated inside the tumor cells, such as the lysosomal protease 
cathepsin B. In serum conditions (pH 7.5) these proteases are inactivated due to the 
presence of different protease inhibitors, for this reason the peptide linker is stable 
in systemic circulation and it is only cleaved upon internalization in tumors. In 2011, 
the FDA approved the ADC Adcetris® containing a Val-Cit linker connected to the 
self-immolative p-aminobenzylcarbamate-monomethyl auristatin E and an anti-
CD30-mAb.34,69 
 
Figure 12. Enzymatic cleavage and drug release of paclitaxel prodrug containing the peptide linker 
[D]-Ala–Phe–Lys. Prodrug [D]-Ala-Phe-Lys-PABC-PTX a undergoes enzymatic cleavage giving b, 1,6-
elimination of self-immolative p-aminobenzylcarbamate moiety gives the metabolite c. Finally, 





Corso; M. Caruso; L. Belvisi et al. Chem. - A Eur. J. 2015, 21 (18), 6921–6929. Copyright © 2015 John 
Wiley and Sons. 
- Non-cleavable linkers: alkyl or polymeric moieties that liberate the payload only 
after lysosomal degradation of the conjugate inside the cell. Their main advantage is 
the increased plasma stability compared to cleavable linkers71 and the specificity of 
the drug release mechanism. This type of linker has been successfully used in ADCs, 
notably in trastuzumab emtansine (Kadcyla®), that contains a non-reducible 
thioether, N-succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC 
or MC after conjugation), that connects the antibody with the maytansinoid DM1.72  
1.4.4. Payload selection 
The choice of the cytotoxic drug depends on the molecular target and the chemical 
structure of the conjugate. The drug is expected to exert a potent cytotoxic activity 
after internalization via receptor-mediated endocytosis, which means that a good 
membrane permeability is needed to diffuse across the endosomal membranes and 
some organelles (e.g. mitochondrion or nucleus). In addition, its chemical properties 
must afford an easy conjugation to the linker or self immolative moiety, for example 
through functional groups like hydroxyl, carboxyl, amines, carbonyls or thiols. In some 
cases it is also necessary to regulate the hydrophobicity of the payload to improve the 
conjugate’s pharmacokinetics, this can be achieved by introducing hydrophilic PEG 
spacers.18,50  
Among the cytotoxic drugs used in SMDC currently in clinical trials there are antimitotic 
agents such as paclitaxel, docetaxel, tubulysin B and desacetyl vinblastine hydrazide; 
and DNA damaging agents like ifosfamide and mitomycin C (Figure 13).50 However, 
promising cytotoxic agents with higher potency (IC50 < 10-9 M) are also being evaluated 
as payloads for SMDCs. This is the case of the tubulin polymerization inhibitors 
monomethyl auristatin E (MMAE),58,73 cryptophycins74 and maytansinoids (e.g. 







Figure 13. Cytotoxic drugs used in SMDCs 
1.4.5. SMDCs in clinical trials 
At present there are nine SMDCs in different stages of clinical trials (Table 1).47,50 Most 
of these conjugates target the vitamin folate receptor alpha (FRα) overexpressed in a 
variety of human tumors (e.g. ovary, lung, kidney, endometrium, colon and breast) and 
have been developed by Endocyte. Their lead candidate EC145, also known as 
vintafolide, contains the vitamin folic acid conjugated to desacetyl vinblastine 
monohydrazide (DAVBH) via a dithiol cleavable linker. It is currently  in Phase II testing 
against non-small-cell lung carcinoma and solid tumors.76  
Table 1. Small molecule-drug conjugates in clinical trials50,77 
Conjugate Target Ligand Cytotoxic agent State 
Glufosfamide Glut1 β-D-glucose Ifosfamide 
Phase 3: metastatic 
pancreatic cancer 
Phase 2: GM, 
pancreatic cancer 
and soft tissue 
sarcoma 






NGR-TNF APN NGR TNF-α 
Phase 2: metastatic 
ovarian cancer, 
metastatic SCLC, 




Phase 1: advanced 
solid tumors 
GRN1005 LRP1 Angiopep2 Paclitaxel 




BIND 014 PSMA DUPA 
Liposomal 
docetaxel 
Phase 2: prostate 
cancer, NSCLC 
EC1169 PSMA DUPA Tubulysin 
Phase 1: recurrent 
MCRPC 











Phase 1: recurrent 
or refractory solid 
tumors 
EC0225 FR Folic acid 
DAVBH and 
mitomycin C 
Phase 1: refractory 
or metastatic solid 
tumors 
EC0489 FR Folic acid DAVBH 
Phase 1: refractory 
or metastatic solid 
tumors 
EC1456 FR Folic acid tubulysin 
Phase 1: solid 
tumors, NSCLC, 
ovarian cancer 
Glut1 = glucose transporter 1, TNF = tumor necrosis factor, APN = aminopeptidase N, LRP1 = low-density lipoprotein 
receptor-related protein 1, PSMA = prostate-specific membrane antigen, DUPA = 2-[3-(1,3-
dicarboxypropyl)ureido]pentanedioic acid, DAVBH = desacetylvinblastine hydrazide, GM = glioblastoma multiforme, 
SCLC = small-cell lung cancer, NSCLC = nonsmall-cell lung cancer, HCC = hepatocellular carcinoma, FR = folate receptor, 








Endocyte has also developed a SMDC targeting the prostate specific membrane antigen 
(PSMA). EC1169 is constituted by the ligand DUPA and tubulysin B hydrazide as a 
payload, and it is currently in Phase I clinical trials for recurrent metastatic castration-
resistance prostate cancer (MCRPC) patients.78,79 Another SMDC targeting the PSMA is 
BIND 014, developed by Bind Therapeutics. This conjugate containing DUPA and a 
docetaxel-based nanoparticle payload, has recently shown acceptable safety in phase II 
with MCRPC patients.80 
NGR-TNFα is a SMDC developed by Corti and coworkers81 that targets the 
aminopeptidase-N (APN), overexpressed on the vasculature of several human cancers. 
It contains a small peptide ligand formed by the sequence Asn-Gly-Arg, conjugated to 
the tumor necrosis factor α (TNFα), a multifunctional cytokine that plays a key role in 
apoptosis and cell survival, as well as in inflammation and immunity.82 This compound 
has shown promising activity in Phase I clinical trials in combination with doxorubicin for 
treatments of solid tumors.81 Other peptide-drug conjugate in clinical evaluation is GRN 
1005 (or ANG 1005), developed by Angiochem and containing three molecules of 
paclitaxel bound to the 19-aminocid sequence angiopep2 that targets the low-density 
lipoprotein receptor-related protein 1 (LRP-1).83 This conjugate has been recently tested 
in non-small cell lung cancer patients with brain metastasis (GRABM-L). 
The progress of SMDCs in the pipeline of new therapeutics reassures the validity of this 
approach. Furthermore, the increasing diversity of ligands, spacers, linkers and payloads 
now available makes possible the design of novel and more efficient conjugates with 
improved affinity for their specific targets and better control of drug delivery and 







Chapter 2. Tumor targeting with integrin ligands 
 
2.1. Role of integrins in cancer  
Integrins are cell surface receptors constituted by α and β subunits associated in a non-
covalent manner. Both subunits are type I transmembrane glycoproteins that contain 
an extracellular domain, a single transmembrane domain and a short intracellular tail. In 
vertebrates, 18 α subunits and eight β subunits form 24 integrin αβ heterodimers 
expressed in different tissues.84,85 Each integrin exhibits a distinct binding affinity to 
particular ligands determined mostly by the α subunit (Figure 14), defining integrin 
subfamilies with specificity for Arg-Gly-Asp (RGD) motifs (αIIb, αV, α5, α8), intercellular 
adhesion molecules and inflammatory ligands (α4, αL, αM, αX, and αD), collagens (α1, α2, 
α10, α11) and laminins (α3, α6, α7).86 
 
Figure 14. Schematic representation of two integrins subunits and the 24 members of integrin family86 
Integrins play an important role in cell adhesion (cell-cell, cell-ECM), migration, survival 
and growth. After binding to ECM proteins (e.g. fibronectin and vitronectin) or cell 
surface immunoglobulin proteins (e.g. ICAM-1 and VCAM-1), integrins initiate a 
signaling cascade that can include tyrosine phosphorylation of focal adhesion kinases 
(FAK) and interaction with growth factors receptors (GFRs).87,88 They mediate a 





exchanging information between the ECM and intracellular molecules.89,90 These 
complex signaling pathways allow the control of cell polarity, mobility, ECM remodeling 
and assembly that results in cell survival and proliferation.91 During the last two 
decades, integrins have gained increasing attention in pharmacological research since 
some integrins, notably αVβ3, α5β1 and αVβ6, are overexpressed in a variety of cancers 
contributing to progression and metastasis (Table 2).92,93   
Table 2. Integrins in cancer progression92 
Tumor Type Integrin expressed 
Melanoma αVβ3, α5β1 
Breast αVβ3, α6β4 
Prostate αVβ3 
Pancreatic αVβ3 
Ovarian αVβ3, α4β1 
Cervical αVβ3, αVβ6 
Glioblastoma αVβ3, αVβ5 
Non-small-cell lung carcinoma α5β1 
Colon αVβ6 
The integrin receptor αVβ3, first identified by Ruoslahti and coworkers,94 is widely 
expressed on blood vessels of tumor cells (e.g. breast, glioblastoma, ovarian, prostate 
cancer) but not on vessels of normal tissue.95 Integrin αVβ3 is upregulated during tumor 
angiogenesis due to the stimuli of angiogenic growth factors such as fibroblast growth 
factor-2 (FGF-2), tumor necrosis factor α (TNF-α) and interleukin 8 (IL-8) present at 
wounds and inflammation sites. This is a critical step in tumor progression and 
metastasis because it provides oxygen and nutrients to the cells.96,97 Moreover, the 
activation of αVβ3 also facilitates tumor cell migration by regulation of the matrix-
degrading protease MMP2 on the surface of angiogenic blood vessels, resulting in 
collagen degradation and  ECM modification.87,98  
Because its implication in biological functions determinant for cancer progression and 







2.2. Integrin ligands targeting the αVβ3 receptor 
2.2.1. RGD integrin ligands 
2.2.1.1. RGD recognition motif 
In 1987, Ruoslahti reported the tripeptide sequence RGD (Figure 15) as the basic motif 
present in many natural ligands of the αVβ3 receptor such as fibronectin and other cell 
adhesion proteins (e.g. vitronectin, osteopontin, collagen).99 
 
Figure 15. RGD sequence 
The complete understanding of the interactions between RGD and αVβ3, however, was 
only possible in 2002 when Xiong and coworkers100 reported the crystal structure of the 
extracellular segment of the αVβ3 integrin receptor complexed with the αVβ3 integrin 
binder Cilengitide (Figure 16).  
 
Figure 16. Cilengitide–integrin V 3 interaction. A) Surface representation of the RGD ligand-binding 
site; (B) Crystal structure of the V 3 -Cilengitide complex. (ADMIDAS and MIDAS regions are shown in 
violet and cyan respectively; Cilengitide is represented in yellow; αV and β3 residues are labelled in blue 
and red, respectively; O and N atoms are represented in red and blue respectively. Hydrogen bonds and 
salt bridges are represented with dotted lines). Adapted with permission from Jian-Ping Xiong, Thilo 
Stehle et al.; Science. 2002, 296 (5565), 151–155. Copyright © 2002 The American Association for the 






The crystal structure showed an extended conformation of the RGD sequence in the 
binding pocket, with a distance of 9 Å between the Cβ atoms of the Arg and Asp 
residues. This folding allows the guanidine group of Arg to interact with two anionic 
aspartic acid residues in the α-subunit (Asp 218 and Asp150), whereas the aspartic acid 
binds to Mn2+ divalent cation in the metal ion-dependent adhesion site (MIDAS) region 
of the β-subunit. The glycine residue, at the interface between both subunits, presents 
weak hydrophobic interactions with the carbonyl group of Arg216, same than the 
aromatic group of the ligand with Tyr122.100,101 All these integrin-ligand interactions, 
also known as “electrostatic clamp”, suggested structural requirements that constituted 
the starting point for the development of high affinity synthetic αVβ3 integrin ligands. 
2.2.1.2. Cyclic RGD integrin ligands 
Several small molecules, peptides and peptidomimetics containing the RGD sequence  
have been designed to target the integrin ανβ3 either as antagonists or as vehicles for 
selective delivery of drugs and imaging probes to tumors.102,103   
First synthetic RGD ligands were linear peptides that included the RGD-motif and other 
amino acids added to the sequence (e.g. RGD, RGDS, GRGD, GRGDS, GRGDSP, 
GRGDSPK). Whereas linear ligands showed good binding affinity for the ανβ3 receptor, 
also presented low stability regarding enzymatic degradation, resulting in limited 
applicability for in vivo studies.104,105 This led to the use of different strategies including 
cyclization, modification of the stereochemical configuration of the constituent amino 
acids and N-methylation to improve the biological activity of RGD ligands.106,107 
In 1991, Kessler and coworkers developed the cyclic pentapeptide cyclo(RGDfV) (Figure 
17a) which displayed high binding affinity towards ανβ3 (IC50 ανβ3 = 1.54 ± 0.12 nM) 
while retaining selectivity against other integrins (e.g. αIIbβ3, ανβ5, ανβ8).108,109 This base 
structure was later modified to produce new ligands with improved activity and 
selectivity profiles.110 Among them, cyclo[RGDf-(NMe)V] (Cilengitide, Figure 17b) 
showed outstanding binding affinity for ανβ3 (IC50 ανβ3 = 0.61 ± 0.06 nM) and ανβ5 (IC50 
ανβ5 = 8.4 ± 2.1 nM) as well as subnanomolar antagonistic activity for the ανβ3 
receptor.111,112 Cilengitide became the first integrin antagonist to be tested in clinical 





tumors113–115 despite its failure in phase III trial for the treatment of patients with newly 
diagnosed glioblastoma.116  
 
Figure 17. Structure of cyclic RGD ligands c(RGDfV) and c[RGDf-(NMe)V] 
Other RGD ligands reported by the same group are cyclo(RGDfK), cyclo(RGDyK), 
cyclo(RGDfC) (Figure 18, a-c) and RGD4C (Figure 18, d).95,103 The amino group of the 
lysine residue of cyclo(RGDfK) and cyclo(RGDyK) allows further chemical conjugation, 
similarly in the case of cyclo(RGDfC), the thiol group of the cysteine residue is often 
used in the conjugation to maleimide-functionalized linkers via Michael addition. For 
these reason, the mentioned ligands are commonly used as vectors for the delivery of 
therapeutic agents.95,117,118 In 1995, Ruoslahti and coworkers reported the discovery by 
phage display technology of the undecapeptide RGD4C (ACDCRGDCFCG)119, which is 
structurally constrained by two disulfide bonds. RGD4C has been used delivery systems 
by conjugation at its N- or C-terminals.120–123 Furthermore, it can be expressed by 
recombinant methods into proteins and viruses, as in the case of the RGD4C-TNF fusion 
protein,124 used for the targeted delivery of TNF to ανβ3 expressing tumors. 
 






2.2.1.3. Cyclo[DKP-RGD] integrin ligands 
In 2009 our research group reported the synthesis of low-nanomolar peptidomimetics 
where the RGD sequence was cyclized by means of a bifunctional diketopiperazine 
(DKP) scaffold containing a carboxylic and an amino function.125,126  In 2012, a small 
library of different cyclo[DKP-RGD] ligands was reported, differing in the configuration 
at the two DKP stereocenters (position 3 and 6) and in the substituents at the DKP 
nitrogen atoms (Figure 19). The introduction of the DKP scaffold confers metabolic 
stability and conformational rigidity to the ligand, facilitating the interactions needed to 
fit into the RGD pocket of ανβ3 receptor.127,128 In particular, the RGD peptidomimetics 2-
7 derived from trans-DKP scaffolds (DKP2-DKP7) showed a preferential binding affinity 
towards integrin αVβ3, inhibiting the binding of biotinylated vitronectin, a natural 
integrin ligand, to the purified αVβ3 at low-nanomolar IC50 values in a competition 
binding assay (Table 3).127 
 
Figure 19. Library of cyclo[DKP-RGD] integrin ligands 
Table 3. Inhibition of biotinylated vitronectin binding to ανβ3 and ανβ5 receptors126,127 
Compound N° Structure 
ανβ3 IC50  
[nM] 
ανβ5 IC50  
[nM] 
1 cyclo[DKP1-RGD] 3898 ± 418 >104 
2 cyclo[DKP2-RGD] 3.2 ± 2.7 114 ± 99 
3 cyclo[DKP3-RGD] 4.5 ± 1.1 149 ± 25 
4 cyclo[DKP4-RGD] 7.6 ± 4.3 216 ± 5 
5 cyclo[DKP5-RGD] 12.2 ± 5.0 131 ± 29 
6 cyclo[DKP6-RGD] 2.1 ± 0.6 79 ± 3 
7* cyclo[DKP7-RGD] 
a) 220.2 ± 82.3 
b) 0.2 ± 0.09 
a) >104 
b) 109 ± 15 





- cyclo(RGDfV) 3.2 ± 1.3 7.5 ± 4.8 
[a]IC50 values are calculated as the concentration of compound required for 50% inhibition of 
biotinylated vitronectin binding. * Two diastereoisomers detected. 
NMR characterization and conformational studies performed on the cyclo[DKP-RGD] 
ligands 1-8 revealed that the ligands with highest affinity values (trans configuration) 
displayed well-defined preferential conformations with an average distance of 8.8Å 
between Cβ(Arg) and Cβ(Asp) consistent with an extended arrangement of the RGD 
sequence (Figure 20).127   
 
Figure 20. Structures obtained by restrained MC/SD simulations based on NOESY spectra distance 
information127 
Docking studies were performed based on the representative conformations obtained 
from the MC/SD simulations. During these studies the ligand cyclo[DKP3-RGD] 3, 
produced top-ranked poses displaying all the important interactions RGD- αVβ3 integrin, 
taking as a reference the crystal structure of the extracellular segment of the αVβ3 






Figure 21. Best pose of compound cyclo[DKP3-RGD] into the crystal structure of avb3 integrin overlaid on 
Cilengitide (green tube representation). 
 
In further biological evaluation, the c[DKP3-RGD] ligand 3 was tested for its effect on 
cell viability, proliferation, migration and capillary network formation; mRNA expression 
of αV, β3 and β5 subunits and Akt phosphorylation in human umbilical vein endothelial 
cells (HUVEC). Results showed that cyclo[DKP3-RGD] significantly inhibit the cell 
adhesion and angiogenesis induced by growth factors (VEGF, EGF, IGF-I, FGF2 and IL-8) 
as well as the phosphorylation of Akt, a protein kinase important in the regulation of 
vascular homeostasis and angiogenesis.129 Recent studies demonstrated that c[DKP3-
RGD] was able to inhibit also the FAK/Akt integrin-activated transduction signaling 
pathway and integrin-mediated cell infiltration process in U373 human glioblastoma cell 
line, reinforcing  its condition of true integrin αvβ3 antagonist.130 
The former results increased the interest in cyclo[DKP3-RGD] 3 as a potential vehicle for 
the delivery of cytotoxic agents. For this purpose the DKP3 scaffold was modified by 
substituting one amine proton with a benzylamine moiety, obtaining the functionalized 
c[DKP-f3-RGD] ligand (9, Figure 22)131 that has been used in the preparation of SMDCs 
targeting the αvβ3 receptor.70,132,133 
 





2.2.1.4. RGD integrin ligands in SMDCs 
The recognition of integrins as potential targets for cancer treatment has led to the 
development of drug delivery systems based on RGD integrin ligands that can 
selectively target the tumor cells overexpressing the ανβ3 receptor and release the 
cytotoxic agent into the cell after internalization via receptor-mediated endocytosis.134 
Some examples of RGD-drug conjugates are presented in this section, including the 
work developed by our research group in the field. (An extended review about RGD 
conjugates used in drug delivery and theranostics can be found in references 
95,102,117,135–137. 
- RGD-Doxorubicin conjugates 
Two conjugates containing the doxorubicin prodrug doxsaliform (DOXSF) and RGD 
ligands were reported by Burhart and co-workers in 2004.138 The linker in this case was 
the N-Mannich base of doxsaliform that released DOX upon hydrolysis. The conjugates, 
DOXSF-acyclicRGD4C and DOXSF-c[RGDf(N-Me)V] (Figure 23, a-b), displayed good 
binding affinity values in a vitronectin cell adhesion assay (IC50 = 5 nM and 10 nM 
respectively) and resulted slightly more toxic compared than the free DOX in a cell 
viability assay carried out in MDA MB-435 cell line. Later, Ryppa and co-workers139 
reported the synthesis of two DOX-E[c(RGDfK)]2 conjugates. In one of them DOX was 
attached to the ligand through an amide bond (Figure 23, c) while in the second one the 
linker used was a MMP2/MMP9 cleavable octapeptide (Figure 23, d). The conjugate 
bearing the protease cleavable linker demonstrated to be more efficient in the HUVEC 
antiproliferative, however, it displayed a moderate antitumor activity compared to free 






Figure 23. RGD-DOX conjugates 
- RGD-MMAE conjugates 
In 2014, Tsien’s group developed the cyclic RGD conjugate RGD-PLGC(Me)AGMMAE-
ACPP (Figure 24),140 a dual targeting conjugate containing the potent tubulin 
polymerization inhibitor MMAE, an activable cell penetrating peptide (ACPP) targeting 
the MMP2, a far-red fluorescent dye (Cy5) and the cyclic(RGDfC) integrin ligand, for 
theranostic applications. The drug is connected to the ACPP via a maleimide-Val-Cit-PAB 
cleavable linker, whereas the cyclic RGD and Cy5 are connected to ACPP through PEG 
and maleimide linkers.  The conjugate showed better cellular uptake compared with 
cyclic-RAD-PLGC(Me)AG-MMAE-ACPP, the negative control for αvβ3 targeting, in 
U87MG cell line. During in vivo experiments, the conjugate reduced tumor volume in 
40% compared to the control group in MDA-MB-231 orthotopic human breast tumor 






Figure 24. Cyclic RGD-PLGC(Me)AG-MMAE-ACPP conjugate 
- RGD-camptothecin conjugates 
In 2010 Dal Pozzo and co-workers presented the synthesis of five camptothecin (CPT) 
conjugates with c(RGDfV) analogues, bearing an uncleavable amide (Figure 25, a-c) or 
an hydrazone linker (Figure 25, d-e). All the conjugates showed good binding affinity for 
the αvβ3 receptor, but only the conjugates containing the hydrazone acid labile linker 
displayed a cytotoxicity superior to free CPT in A2780 ovarian carcinoma, A498 renal 
carcinoma and PC3 prostate carcinoma cell lines. However, the acid labile conjugates 
showed poor solubility and stability even at pH 7.4, which suggests the high cytotoxicity 






Figure 25. RGD-CPT conjugates 
Recently, Gennari’s group reported the synthesis and in vitro evaluation of two 
theranostic RGD-camptothecin conjugates (Figure 25, f-g), conformed by cyclo(RGDfK) 
or c[DKP-RGD]-CH2NH2 9 and a fluorescent naphthalimide moiety bound to CPT via a 
disulfide linker. Both conjugates exhibited a good binding affinity for integrin αvβ3, 
inhibiting the binding of biotinylated vitronectin to the purified receptor at nanomolar 
concentrations (IC50 5-21 nM). Nevertheless, in cell viability assays carried out in U87 
(αvβ3+) cell line and αvβ3 non- expressing clone U87 β3-KO the conjugates showed an 
antiproliferative activity similar to the free CPT and not dependent on the αvβ3 
expression. These results were consistent with confocal microscopy and 
immunofluorescence internalization studies where it was not observed a correlation 
between the internalization and the expression of αvβ3.132 
- RGD-Paclitaxel conjugates 
In 2012, the synthesis and biological evaluation of SMDC based on the c[DKP-RGD]-
CH2NH2 9 and paclitaxel connected by an acid-labile ester linker was reported by the 
groups of Gennari and Piarulli. The conjugate c[DKP-RGD]-CH2NH2-PTX (Figure 26, a) 
displayed a binding affinity for the αvβ3 receptor comparable to the ligand non-
functionalized c[DKP3-RGD] 3 (IC50 αvβ3: 5.2 and 4.5 nM respectively) and a selectivity 
towards integrin αvβ3 compared to αvβ5 (IC50 αvβ5: 219 nM). Cell viability tests 





SKOV3, PANC-1 and MIA-PaCa2) showed that the conjugate exert a cytotoxicity similar 
to the free PTX. However, in vivo studies carried out on IGROV-1/Pt1 carcinoma 
xenotransplanted in nude mice showed that the conjugate c[DKP-RGD]-CH2NH2-PTX was 
more effective than PTX, inhibiting tumor growth at 15 mg/kg-mouse doses. Moreover, 
the histopathological analysis of tumors from treated mice revealed the existence of 
aberrant mitotic cells, which is consistent with PTX mechanism of action.131  
 
Figure 26.cyclo[DKP-RGD]-PTX conjugates 
The same groups developed in 2015 two c[DKP-RGD]-PTX conjugates containing the 
ligand 9 bound to PTX through lysosomally cleavable dipeptide linkers: Val-Ala and Phe-
Lys (Figure 26, b-c). Additionally, a c[DKP-RGD]-PTX conjugate containing an 
‘uncleavable’ nonpeptide linker was synthetized as a negative control of the linker 
efficacy (Figure 26, d). In the competitive binding assay, the three conjugates displayed 
slightly lower binding affinity than the unconjugated ligand 9, remaining in the low 
nanomolar range and conserving the selectivity towards αvβ3 compared to αvβ5. The 
conjugates bearing the dipeptide linkers were stable at different pH conditions and 
showed an efficient linker cleavage and release of the drug after treatment with 
lysosomal extract. The antiproliferative activity of the conjugates was evaluated on two 
isogenic cell lines expressing different levels of αvβ3: acute lymphoblastic leukemia cell 
line CCRF-CEM (αvβ3-) and its sub-clone CCRF-CEM (αvβ3+). The conjugate bearing the 





dipeptide cleavable linkers displayed an antiproliferative activity similar to free PTX with 
an increased potency in CCRF-CEM (αvβ3+) compared to the negative cell line. These 
results suggested an integrin-targeting effect presented by the conjugates.70  
2.2.2. isoDGR integrin ligands 
2.2.2.1. IsoDGR sequence: a new αVβ3 recognition motif 
In 2006 Corti and co-workers identified the isoAsp-Gly-Arg sequence (Figure 27) 
resulting from the spontaneous transformation of the NGR (Asn-Gly-Arg) portion of 
fibronectin, as a new binding motif recognized by the αVβ3 receptor.142   
 
Figure 27. isoDGR sequence 
 
In effect, the asparagine residue of NGR can undergo a non-enzymatic deamidation at 
physiological pH, passing through the formation of a succinimide intermediate that 
generates isoDGR and DGR tripeptides mostly in L-configuration after hydrolysis (Figure 
28). In the fifth type I fibronectin (FN-I5), the NGR deamidation of Asn263 was 
associated to the increase of cell-adhesion after an accelerated aging process (heat-
induced treatment). The gain of function in cell adhesion indicated αVβ3 integrin binding 
that could be attributed to isoDGR or DGR motif, however, competitive binding tests 
performed on synthetic peptides containing the isoDGR, DGR and iso-dGR (D-isoDGR) 
sequences showed a superior binding affinity of isoDGR for the αVβ3 receptor (in the 
sub-micromolar range). These results led to the conclusion that isoDGR is a αVβ3 binding 







Figure 28. Schematic representation of the NGR deamidation reaction 
In order to determine if the interaction of the isoDGR motif with the αVβ3 integrin 
receptor occurred at the binding site of the RGD sequence, a competitive binding test 
was carried out with the cyclopeptides RGD-2C (CRGDCGVRY) and isoDGR-2C 
(CisoDGRCGVRY), in presence of a known αVβ3 integrin binder: ACDCRGDCFC-TNF. 
Results showed that both ligands, RGD-2C and isoDGR-2C, were able to inhibit the 
binding of ACDCRGDCFC-TNF to αVβ3, displaying similar binding affinity values (Kd RGD = 
0.41 µM, Kd isoDGR = 0.57 µM) suggesting that the isoDGR motif binds to αVβ3 at the 
site of RGD. The same study demonstrated that isoDGR can also bind the integrin αVβ5 
at the binding site of RGD but with less affinity than in the case of αVβ3.142 
In addition to biological evaluation, structural NMR analysis and docking studies 
performed on RGD-2C and isoDGR-2C confirmed that isoDGR binds the integrin αVβ3 
fitting into the RGD pocket.144 The model of the ligands in complex with αVβ3 (Figure 29) 
showed that isoDGR-2C displays a reversed orientation compared to RGD-2C, 
preserving all the interactions previously described for RGD: isoAsp residue coordinates 
with the metal ion of the MIDAS region of the β domain through its carboxylate and 
forms hydrogen bonds with Asn215, Tyr122 and Arg214, whereas Arg residue forms a 
bidentate salt bridge with Asp218 and an hydrogen bond with Asp150 and Gln180 at 
the α subunit. Interestingly, the isoDGR motif established additional interactions such as 
an hydrogen bond between the amide proton of the glycine residue and the carbonyl 






Figure 29. Model for the interaction for isoDGR and RGD at integrin αvβ3 binding site.  Representation of 
the αvβ3-binding pocket in complex with CisoDGRC (left) or CRGDC (right). αv and β3 subunits are 
represented in pink and pale cyan respectively; RGD and isoDGR motifs are shown in green; cystine in 
gray; N, O and S atoms in blue, red and yellow respectively; Ca2+ of MIDAS region is represented by a red 
sphere; hydrogen bonds are represented by dotted lines. Adapted with permission from A. Spitaleri; S. 
Mari; F. Curnis et al. J. Biol. Chem. 2008, 283, 19757–19768 Copyright © 2008 The American Society for 
Biochemistry and Molecular Biology, Inc. 
The finding of isoDGR as an alternative motif for integrin recognition encouraged the 
research for new αVβ3 ligands based on this motif. The group of Corti developed in 2010 
a small library of isoDGR ligands conformed by: acisoDGR-2C, a derivate of the isoDGR-
2C with an acetyl group linked to the α-amino group of the cysteine residue (Figure 30); 
isoDGR-2G and the respective acisoDGR-2G. Competitive binding tests performed on the 
four compounds showed that isoDGR-2C presented 10–100-fold higher binding affinity 
values for  αVβ3 than for other integrins (i.e. αvβ5, αvβ6, αvβ8, α5β1) while isoDGR-2G 
displayed a weak binding affinity for αVβ6 and no binding affinity for αVβ3. The 
acetylated compounds presented an increased binding affinity for all integrins with loss 
of selectivity. These results suggested that flanking residues had an influence on the 
binding affinity and selectivity of the ligands.146  
 
Figure 30. Integrin ligand isoDGR-2C (CisoDGRCGVRY) and its derivate acisoDGR-2C (acCisoDGRCGVRY)  
Further computational and biochemical studies performed on isoDGR-2C and acisoDGR-





activation, acting as true αvβ3 antagonists.147 In 2013 the same group reported the 
synthesis of a cyclic hexapeptide containing the isoDGR sequence, cyclo(CGisoDGRG),148 
that showed preferential binding affinity for αvβ3 compared to αvβ5 and α5β1, and was 
used for the preparation of peptide-HSA (human serum albumin) conjugates with 
potential application in drug delivery. Moreover, recent studies have demonstrated that 
the antagonist condition is an inherent property of the isoDGR ligands, independent of 
the scaffold or chemical entities accompanying the tripeptide sequence.149 This 
characteristic constitutes a main advantage of isoDGR integrin ligands over their RGD 
pairs, considering adverse effects (e.g. angiogenesis, tumor growth) associated to a 
partial agonist-like activity detected for some RGD-based peptidomimetics.150   
2.2.2.2. Cyclo[DKP-isoDGR] integrin ligands 
Based on the cyclo[DKP-RGD] library previously reported, our research group produced 
a small library of four cyclo[DKP-isoDGR] integrin ligands (Figure 31).130,151  
 
Figure 31. Cyclo[DKP-isoDGR] integrin ligands 
The ligands 10-13 were evaluated for their ability to inhibit the binding of biotinylated 
vitronectin to isolated αvβ3 and αvβ5 receptors in a competitive binding assay (Table 4). 
The compound 11, structural analogue of c[DKP3-RGD] (3), displayed a preferential 
binding affinity for αvβ3 than for the αvβ5 receptor. Also, it showed better affinity values 
(low-nanomolar IC50) than the other c[DKP-isoDGR] ligands and the cyclopentapeptide 






Table 4. Inhibition of biotinylated vitronectin binding to ανβ3 and ανβ5 receptors130 
Compound  Structure 
ανβ3 IC50 [a] 
[nM] 
ανβ5 IC50 [a] 
[nM] 
10 c[DKP2-isoDGR] 46.7±18.2 220±84 
11 c[DKP3-isoDGR] 9.2±1.1 312±21 
12 c[DKP5-isoDGR] 490±77 9100±800 
13 c[DKP7-isoDGR] 255±140 5100±400 
3 c[DKP3-RGD] 4.5±1.1 149±25 
 c[RGDfV] 3.2±1.3 7.5±4.8 
 c[GisoDGRphg] 89 ± 19* n.d. 
 Cilengitide 0.6±0.1 11.7±1.5 
[a]IC50 values are calculated as the concentration of compound required for 50% inhibition of 
biotinylated vitronectin binding. *determined by a solid phase binding assay by using supported 
vitronectin, soluble αvβ3 integrin, specific primary and secondary antibodies.152 n.d. = non determined 
To get a better understanding of the interactions responsible for integrin binding 
affinity of c[DKP3-isoDGR] (11), conformational NMR spectroscopy and docking 
experiments were performed.151 NMR data and MC/SD simulations indicated the 
existence of two preferred conformations for 11: a distorted β-turn at Gly-Arg and a 
pseudo-β-turn at DKP-isoAsp (Figure 32). About 80% of the simulations adopted an 
extended arrangement of the isoDGR sequence (pseudo-β-turn), with an average 
distance Cβ(Arg)-Cβ(Asp) of 10.8 Å. 
 
Figure 32. NMR conformational studies on 11. I) Preferred intramolecular hydrogen-bonded pattern 





turn at DKP-isoAsp; II) MC/SD simulations based on experimental distance information after energy 
minimization: a) Distorted β-turn (10% of the simulations), distance Cβ(Arg)-Cβ(Asp) = 10.7 Å; b) pseudo-
β-turn, (80% of the simulations), distance Cβ(Arg)-Cβ(Asp) = 10.8 Å.151 Adapted with permission from M. 
Mingozzi; A. Dal Corso; M. Marchini et al. Chem. - A Eur. J. 2013, 19, 3563–3567. Copyright © 2013 
WILEY-VCH Verlag GmbH & Co. 
Docking studies were performed based on the conformations of 11 obtained from the 
MC/SD simulations and taking as a reference the crystal structure of the extracellular 
segment of the αVβ3 integrin receptor complexed with the peptide binder Cilengitide for 
the ligand-protein interactions. In the case of the distorted β-turn Gly-Arg 
conformation, it conserved main electrostatic interactions corresponding to RGD 
binding model, but it lacked the hydrogen bond interactions with the β3 subunit. 
Instead, the pseudo-β-turn DKP-isoAsp conformation presented all the interactions 
described for the X-ray complex of integrin-Cilengitide (Figure 33) including the 
interaction of the guanidium group with the carboxylates of Asp218 and Asp150 in the 
α unit, the coordination of a carboxylate oxygen of the ligand to the metal cation of the 
MIDAS region of the β subunit, the hydrophobic interactions with Asn215 and Tyr122 of 
the β unit, and additional hydrogen bond between the amide proton of the Gly residue 
and the carbonyl group of Arg216 of the β subunit.151 
 
Figure 33. Best pose of c[DKP3-isoDGR] (11) pseudo-β-turn conformation into the crystal structure of 
the extracellular domain of αvβ3 integrin (α unit in pink and β unit in blue), overlaid on the bound 
conformation of Cilengitide (green tube representation). The metal ion in the MIDAS region is 
represented by a magenta sphere. Adapted with permission from M. Mingozzi; A. Dal Corso; M. 
Marchini et al. Chem. - A Eur. J. 2013, 19, 3563–3567. Copyright © 2013 WILEY-VCH Verlag GmbH & Co. 
Recently, our research group carried out a series of biological studies to evaluate the 
antiangiogenic and integrin antagonist activity of the ligands c[DKP3-isoDGR] (11) and 





MTS cell viability tests performed in U373 glioblastoma cell line indicated no cytotoxicity 
of the compounds 3 and 11, as expected for integrin antagonists.129,153 In fact, ELISA 
nucleosome assays showed a significant increase of nucleosome content after 72 hours 
treatment, suggesting that both ligands could induce cell apoptosis (Figure 34). 
 
Figure 34. ELISA nucleosome assay. Nucleosome content after 72h treatment with A: c[DKP3-RGD] (3) 
and B: c[DKP3-isoDGR] (11). ** calculated probability value P>0.005.130 Adapted with permission from S. 
Panzeri; S. Zanella; D. Arosio et al. Chem. - A Eur. J. 2015, 21, 6265–6271. © 2015 WILEY-VCH Verlag 
GmbH & Co. 
Infiltration assays conducted on U373 cell line showed a marked inhibitory effect on cell 
migration and cell infiltration processes for ligand 3 and 11 at 10 µM concentration, 
remaining basically unchanged at 25 µM (Figure 35). 
 
Figure 35. Infiltration assay. A: c[DKP3-RGD] (3); B: c[DKP3-isoDGR] (11); *** calculated probability value 
P>0.001.130 Adapted with permission from S. Panzeri; S. Zanella; D. Arosio et al. Chem. - A Eur. J. 2015, 
21, 6265–6271. © 2015 WILEY-VCH Verlag GmbH & Co. 
Compounds 3 and 11 were also tested for their ability to inhibit FAK and Akt 
phosphorylation in U373 cell lines. FAK is a cytoplasmic tyrosine kinase involved in cell 
motility, survival and proliferation. The activation of FAK signaling cascade is regulated 
by integrin-ECM interactions and it plays a key role in tumor cell growth, progression, 
and metastasis.154 Integrin activation of FAK derives in the activation of Akt signaling 
cascade which is involved in the regulation of vascular homeostasis and angiogenesis. 





ligand mediated integrin activation129. In the case of the tested compounds, both 
ligands demonstrated to inhibit the FAK and Akt phosphorylation after 24h treatment 
(Figure 36). 
 
Figure 36. FAK and Akt phosphorylation inhibition. A: c[DKP3-RGD] (3); B: c[DKP3-isoDGR] (11); 
*calculated probability value P>0.5, **calculated probability value P>0.005, ***calculated probability 
value P>0.001. Adapted with permission from S. Panzeri; S. Zanella; D. Arosio et al. Chem. - A Eur. J. 
2015, 21, 6265–6271. © 2015 WILEY-VCH Verlag GmbH & Co. 
These results indicate that c[DKP3-isoDGR] (11), same as its analog c[DKP3-RGD] (3),  
displays an integrin antagonist activity which is consistent with previous studies 
reporting that cyclic isoDGR peptide ligands are true αVβ3 antagonists.147  
This feature together with the high binding affinity and selectivity of c[DKP3-isoDGR] 
towards integrin αVβ3 makes this ligand a suitable candidate for its use in targeted drug 
delivery via SMDCs.   
2.3. Synthesis of a functionalized cyclo[DKP-isoDGR] integrin ligand 
Based on the biological results of cyclo[DKP3-isoDGR] 11 and the work realized with the 
functionalized integrin ligand cyclo[DKP-f3-RGD] 9 (see Section 2.2.1.4), our research 
group reported in 2017 the synthesis of a SMDC bearing a functionalized cyclo[DKP-
isoDGR] integrin ligand (14, Figure 37), a cleavable Val-Ala linker and Paclitaxel as a 
payload.155 The antiproliferative activity of this conjugate was evaluated in vitro on 
isogenic αVβ3-expressing and αVβ3-non expressing cell lines. The cyclo[DKP-isoDGR]-Val-
Ala-PTX conjugate showed higher selectivity towards the αvβ3-expressing cell line 
(targeting index = 9.9) compared to the related cyclo[DKP-RGD]-Val-Ala-PTX conjugate 






Figure 37. Cyclo[DKP-f3-isoDGR] (c[DKP-isoDGR]-CH2NH2) integrin ligand (14) 
Prompted by these promising results we decided to investigate the efficacy of the 
cyclo[DKP-isoDGR] integrin ligand as a vector in the preparation of SMDCs bearing 
different cytotoxic agents. The first part of my PhD project consisted then in scaling up 
the synthesis of the isoDGR ligand 14 containing the benzylamine handle that allows its 
conjugation to other chemical entities.  
2.3.1. Synthesis of DKP-f3 scaffold 
The synthesis of the functionalized DKP-f3 scaffold was achieved as presented in 
Scheme 1, starting from commercially available D-aspartic acid and L-serine methyl 
ester131. 
 
Scheme 1. Synthesis of DKP-f3 scaffold: (a) Allyl alcohol, acetyl chloride; (b) Boc2O, TEA, dioxane, water, 
79% over two steps; (c) NaBH(OAc)3, THF, 3 h, rt.; (d) HATU, HOAT, DIPEA, DMF, 3 h, 0 °C to rt.; (e) 
TFA/DCM 1:2, 3 h, 0 °C to rt.; (f) DIPEA, iPrOH, overnight, rt., 89% over two steps; (g) HN3·Tol, DIAD, 
Ph3P, DCM/Toluene 1:2, 4 h, −20 °C; (h) Me3P, BOC-ON, THF, 3 h, −20 °C to rt.  
The side chain of the aspartic acid was protected with an allyl group before N-Boc 
protection to give the compound 15. On the other hand, the aldehyde 16 undergoes a 
reductive amination with L-serine methyl ester using sodium triacetoxyborohydride to 





coupling conditions (HATU, HOAt, DIPEA) to afford the isopeptide 18 in high yield (84%). 
The selective acylation of the unprotected β-hydroxy group of the functionalized serine 
occurs instead of the expected peptide bond formation, this was reported also in the 
synthesis of DKP1-3.127,156 Next, the Boc protecting group of 18 was cleaved, then O,N-
acyl migration and subsequent ring closure were prompted by treatment with DIPEA in 
isopropyl alcohol156, giving the DKP-f3-OH 19 (89% over two steps). The hydroxyl group 
of 19 was substituted by an azide group via a Mitsunobu reaction using HN3 as 
nucleophile, affording the DKP-f3-N3 20 in satisfactory yield (66%). The reaction was 
carried out at low temperature (-20°C) to avoid the formation of the elimination 
product. The final step was a one-pot Staudinger reduction−Boc protection, allowing to 
reduce the azide under mild conditions and directly react with the 2-(t-butoxy-carbonyl-
oxyimino)-2-phenylacetonitrile (Boc-ON) present in the medium, affording the DKP-f3-
NHBoc 21 in good yield (88%). 
2.3.2. Synthesis of cyclo[DKP-isoDGR] integrin ligand 14 
Once the compound 21 was obtained in gram scale, the synthesis of cyclo[DKP-isoDGR]-
CH2-NH2 (14) continued as indicated in the Scheme 2. Differently from the synthesis of 
cyclo[DKP-isoDGR] 10-13 carried out in solid phase,151 this strategy was entirely 






Scheme 2. Synthesis of c[DKP-f3-isoDGR] (14): (a) TFA, DCM, r.t., 2h; (b) Cbz-Arg(Mtr)-OH; HATU, HOAt, 
DIPEA, DMF, 0 °C to rt., overnight; (c) [Pd(PPh3)4], N-methylaniline, DCM, 0 °C, 1 h; (d) HATU, HOAt, 
DIPEA, DMF, 0 °C to rt., overnight; e) piperidine, DMF, 3 h, rt.; (f) HATU, HOAt, DIPEA, DMF, 0 °C to rt., 
overnight; (g) H2, 10% Pd/C, THF/water 1:1, rt., overnight; (h) HATU, HOAt, DIPEA, DMF (1.4 mM), 0 °C to 
rt., overnight; (i) TFA/TMSBr/thioanisole/EDT/phenol 70:14:10:5:1. 
The DKP-f3-NHBoc 21 was Boc-deprotected and reacted with Cbz-Arg(Mtr)-OH under 
coupling conditions (HATU, HOAt, DIPEA) to give the compound 22 in high yield (85% 
over two steps), then the allyl protecting group was cleaved in presence of N-
methylaniline and [Pd(PPh3)4] to obtain the Arg-DKP fragment 23 (72%). The dipeptide, 
isoAsp-Gly 26, was achieved by regular coupling of Fmoc-L-Asp(OH)-OtBu with glycine 
benzyl ester, followed by cleavage of Fmoc group to afford 26 (80% yield over 2 steps).  
Intermediates 23 and 26 were attached under coupling conditions (HATU, HOAt and 
DIPEA) to give the linear protected compound 27 (83%). Afterwards, the benzyl and Cbz 
protecting groups were removed by palladium catalyzed hydrogenation in water/THF 
1:1 giving the compound 28 in good yield (90%). The linear peptidomimetic was then 
treated with coupling agents (HATU, HOAt, DIPEA) under high dilution conditions (1.4 
mM in 1:1 DCM/DMF) to promote an intramolecular cyclization, giving the cyclic 
intermediate 29 in reasonable yield (68%). Finally, the 4-methoxy-2,3,6-
trimethylbenzenesulphonyl (Mtr) and tert-butyl protecting groups were removed by 





to afford cyclo[DKP-isoDGR]-CH2-NH2 14 as a TFA salt with a yield of 58% after 
purification by reversed-phase HPLC and freeze-drying from water. 
The preparation of the new SMDCs containing the integrin ligand cyclo[DKP-isoDGR]-







Chapter 3. Synthesis of SMDCs based on the functionalized 
cyclo[DKP-isoDGR] integrin ligand 
 
Part of the work described in this Chapter has been published in the following article:157 
- Bodero, L.; López Rivas, P.; Korsak, B.; Hechler, T.; Pahl, A.; Müller, C.; Arosio, D.; 
Pignataro, L.; Gennari, C.; Piarulli, U. Synthesis and Biological Evaluation of RGD and 
IsoDGR Peptidomimetic-α-Amanitin Conjugates for Tumor-Targeting. Beilstein J. 
Org. Chem. 2018, 14 (1), 407–415. 
 
3.1. Synthesis and biological evaluation of isoDGR-α-amanitin conjugates 
3.1.1. α-Amanitin in targeted therapy 
α-Amanitin is the main amatoxin found in the death cap mushroom, Amanita Phalloides 
(Figure 38). Amatoxins are bicyclic octapeptides that present a high thermostability and 
water solubility, besides a resistance to enzyme and acid degradation. For these 
reasons, they can traverse the gastrointestinal tract without suffering any alteration, 
reaching and accumulating in the liver where they display a lethal toxicity, leading to 
hepatic failure after 6-8 days.158,159 In the case of α-amanitin, the LD50 value is 0.1  
mg/kg of bodyweight in humans.160  
 





The mechanism of action of α-amanitin consists in the inhibition of the RNA polymerase 
II, an enzyme present in the nuclei of eukaryotic cells and responsible for the 
transcription of DNA to mRNA.158,161 In effect, α-amanitin binds the RNA polymerase II 
forming a tight complex (Figure 39), causing the inhibition of the elongation step and 
subsequent blocking of the DNA transcription process, resulting finally in cell 
death.159,162,163 However, due to its hydrophilicity and poor membrane permeability, 
cellular uptake of α-amanitin takes place only when it is mediated by a transport 
system, such as the  transporting protein OATP1B3 present on the surface of human 
hepatocytes. For other mammalian cells α-amanitin displays a micromolar cytotoxicity 
associated to poor cellular uptake.161,164 
 
Figure 39. Transport and main toxic mechanism of α-amanitin in hepatocytes. Accumulation of α-
amanitin occurs in the liver upon uptake via the organic anion transporting polypeptide OATP1B3 
located in the sinusoidal membrane of hepatocytes. Once inside the hepatocyte, α-amanitin binds to 
RNA polymerase II causing inhibition of its activity. Adapted with permission from Juliana Garcia, Vera 
M. Costa et al.; Food and Chemical Toxicology, 2015, 86, 41–55. DOI: 10.1016/j.fct.2015.09. Copyright © 
2015 Elsevier Ltd.165 
Because of the strong and specific cytotoxicity achieved upon internalization by 
endocytosis mediators, α-amanitin has become a promising payload for targeted drug 
delivery systems such as ADCs or SMDCs where the monoclonal antibody or the small 
ligand facilitate a receptor-mediated endocytosis and intracellular release of the drug. 
In 1981, Davis and Preston reported the synthesis of an ADC containing an azo-
functionalized α-amanitin (α-amanitinyl-azobenzoyl-N-glycyl-glycine) conjugated to the 
anti-Thy 1.2 immunoglobulin (anti-Thy 1.2 IgG). The conjugate displayed 277-fold and 
47-fold greater toxicity than the unconjugated α-amanitin in the murine T lymphoma 





amanitin-glutarate-chiHEA125 (chiHEA125-Ama), containing a chimeric anti-EpCAM 
(epithelial cell-adhesion molecule) monoclonal antibody, was reported by Moldenhauer 
and coworkers.167 The cytotoxic activity of  this conjugate was tested in different cancer 
cell lines overexpressing EpCAM (i.e. human pancreatic BxPc-3 and Capan-1, colorectal 
Colo205, breast MCF-7 and bile duct OZ) obtaining IC50 values from 2.5 x 10-10 to 5.4 x 
10-12 M, which represented in all cases; an increase of the cytotoxicity compared to 
unconjugated α-amanitin (IC50 2.0 x 10-7 to 5.8 x 10-8 M). Further in vivo studies 
performed in mice bearing BxPc-3 pancreatic xenograft tumors showed complete tumor 
regression in 90% of the mice treated with two injections of chiHEA125-Ama at dose of 
100 μg/kg. The treatment also proved to stop the development of recurrent tumors for 
a 3-4 weeks period without induce systemic toxicity. These two examples of α-amanitin-
based ADCs confirmed the validity of the targeted approach in terms of potency and 
selectivity in comparison to the unconjugated drug. 
Regarding the SMDCs containing α-amanitin as a payload, Reshetnyak and coworkers 
investigated in 2013 three α-amanitin-pHLIP (pH low insertion peptide) conjugates 
bearing different cross-linkers (i.e. cleavable: SPDP, sulfo-Lc-SMPT and non-cleavable 
AMAS).168 In this case, the drug delivery mechanism is the pHLIP mediated direct 
translocation across the cell membrane. The results of antiproliferative tests in human 
cervix adenocarcinoma HeLa-GFP cell line showed an increased cytotoxicity for the 
pHLIP-SPDP-amanitin conjugate at pH 6 compared to pH 7, inducing apoptosis in 48 
hours. On the other hand, the conjugate bearing the uncleavable linker, pHLIP-AMAS-
amanitin, did not display cellular toxicity, which suggested that the activity of the 
conjugates is conditioned to the release of the free amanitin after linker cleavage.  
More recently, Perrin and co-workers reported the synthesis of an amanitin analog 
functionalized with a N-propargyl-asparagine and its conjugation to cyclo(RGDfK) 
through azide-linkers, using a copper-catalyzed azide-alkyne cycloaddition (CuAAC).169 
The antiproliferative activity of the conjugates was evaluated in U87 (αvβ3+) 
glioblastoma cell line, showing only a modest enhancement in the cytotoxicity of the 





3.1.2. Synthesis of cyclo[DKP-isoDGR]-α-amanitin conjugates 
Three cyclo[DKP-isoDGR]-α-amanitin conjugates were prepared in collaboration with 
Heidelberg Pharma AG, by joining the functionalized ligand c[DKP-isoDGR]-CH2-NH2 (14) 
to α-amanitin via an ether group at the 6’-hydroxyindole, using two different linkers: an 
“uncleavable” six carbon aliphatic chain (Figure 40, compound 31) and a lysosomally 
cleavable Val-Ala linker connected to a self-immolative spacer (Figure 40, compounds 
32 and 33).157  
 
Figure 40. Structure of cyclo[DKP-isoDGR]-α-amanitin conjugates 
Compound 31 bearing the uncleavable aminohexyl linker was synthetized as described 
in the Scheme 3. The α-Amanitin 6’-aminohexyl ether (34) provided by Heidelberg 
Pharma AG170,171 reacted with the commercial di-N-succinimidyl glutarate in presence of 
DIPEA to give the pre-activated hemiglutarate-aminohexyl-α-amanitin (35) in high yield 
(90%). For this reaction the activated di-N-succinimidyl glutarate was used in 1.2 
equivalents in order to avoid an undesired substitution of the other hydroxy groups 





spacer already activated as NHS ester in one step, differently from the 2-step procedure 
used in the synthesis of the RGD analogs.157 The resulting intermediate 35 was then 
conjugated to the ligand cyclo[DKP-isoDGR]-CH2NH2 (14) via pH-controlled coupling 
where the pH was maintained in a range of 7.3-7.6 with the addition of small aliquots of 
NaOH 0.2 M to prevent the hydrolysis of the NHS ester that can compete with the 
formation of the amide bond at pH > 7.6, and also because at this pH range the 
guanidinium group of the arginine residue is still largely protonated and does not 
compete with the primary benzylic amine of compound 14. The resulting conjugate 31 
was obtained with 45% yield after HPLC purification and freeze-drying from ACN:H2O 
1/1.  
 
Scheme 3. Synthesis of cyclo[DKP-isoDGR]-uncleavable-α-amanitin (31). Reagents and conditions: a) di-
N-succinimidyl glutarate, DIPEA, DMF, 6 hours, Y: 90%; b) cyclo[DKP-isoDGR]-CH2-NH2 (14), PBS (pH 7.5), 
overnight, Y: 45%. 
The synthesis of the compound 32, containing the lysosomally cleavable Val-Ala linker 
was carried out with the strategy used for conjugate 31 as described in the Scheme 4.  
NH2-Val-Ala-PAB-α-amanitin (36) provided by Heidelberg Pharma AG,170,171 reacted with 
di-N-succinimidyl glutarate in presence of DIPEA to give the hemiglutarate-Val-Ala-PAB-
α-amanitin activated as an NHS ester (37) with 71% yield. Then 37 was conjugated to 
the ligand cyclo[DKP-isoDGR]-CH2NH2 (14) by pH-controlled coupling at pH range of 7.3-
7.6, affording the conjugate 32 in good yield (62%) after HPLC purification and freeze-





cyclo[DKP-isoDGR]-Val-Ala-PAB-α-amanitin (32) is expected to release the unchanged α-
amanitin after intracellular cleavage of the dipeptide linker (mediated by cathepsin B or 
other enzymes) and 1,6-elimination of the PAB self immolative spacer.  
 
 
Scheme 4. Synthesis of cyclo[DKP-isoDGR]-Val-Ala-PAB-α-amanitin (32). Reagents and conditions: a) di-
N-succinimidyl glutarate, DIPEA, DMF, 6 hours, Y: 71%; b) cyclo[DKP-isoDGR]-CH2-NH2 (14), PBS (pH 7.5), 
overnight, Y: 62%. 
For the synthesis of conjugate 33 containing the cleavable Val-Ala linker and the PEG 
spacer, two intermediates were prepared as indicated in the Scheme 5. Val-Ala-PAB-α-
amanitin (36) reacted with 4-pentynoic acid-NHS-ester (39) to give 4-pentynoic acid-Val-
Ala-PAB-α-amanitin (38) with 88% yield. On the other hand, cyclo[DKP-isoDGR]-CH2NH-
PEG-4-N3 (41) was prepared by pH-controlled coupling between the isoDGR ligand 14 
and commercial COOH-PEG-4-azido pre-activated as NHS ester (40). The final step was a 
click reaction, the copper catalyzed alkyne-azide cycloaddition (CuAAC) between the 
azido group of 41 and the alkyne moiety of 38 under inert atmosphere, that gave 
conjugate 33 with 62% yield after HPLC purification and freeze-drying from 
water/acetonitrile 1/1. In this case, the introduction of the PEG chain between the 
linker and the ligand is expected to increase the stability of the conjugate at 
physiological conditions and to give more flexibility to the ligand, facilitating the 






Scheme 5. Synthesis of cyclo[DKP-isoDGR]-PEG-4-Val-Ala-α-amanitin (33). Reagents and conditions: a) 4-
pentynoic acid-NHS ester (39), DIPEA, DMF, overnight, Y: 88 %; b) PBS (pH 7.5), overnight, Y: 46 %. c) 
Sodium ascorbate, CuSO4.5H2O, DMF/H2O 1:1, overnight, Y: 62%. 
3.1.3. In vitro studies 
3.1.3.1. Binding affinity assays 
The isoDGR-α-amanitin conjugates 31-33, as well as the RGD analogs of 31 and 32 
(Figure 41) synthesized by Paula Lopez Rivas (University of Milano), containing the 
cyclo[DKP-RGD]-CH2NH2 integrin ligand 9, were tested in collaboration with the Institute 
of Molecular Science and  Technology of the Italian National Research Council in Milano, 
for their binding affinity towards the integrin αvβ3 in a competitive binding assay that 
measured their ability to inhibit the binding of biotinylated vitronectin to the purified 






Figure 41. Structure of cyclo[DKP-RGD]-α-amanitin conjugates 
The assays were performed by incubating the immobilized αvβ3 integrin receptor with 
solutions of the conjugates cyclo[DKP-RGD]-α-amanitin (42-43) and cyclo[DKP-isoDGR]-
α-amanitin conjugates (31-33) at increasing concentrations (10-12-10-5 M) in the 
presence of biotinylated vitronectin (1 µg mL-1) and measuring bound vitronectin. The 
calculated half-maximal inhibitory concentrations (IC50) are listed in Table 5. 
Table 5. Inhibition of biotinylated vitronectin binding to αvβ3 receptor 
Compound Structure IC50 (nM) [a] αVβ3 
42 cyclo[DKP-RGD]-uncleavable-α-amanitin 11.6 ± 2.4 
31 cyclo[DKP-isoDGR]-uncleavable-α-amanitin 6.8 ± 4.3 
43 cyclo[DKP-RGD]-Val-Ala-α-amanitin 14.7 ± 6.6 
32 cyclo[DKP-isoDGR]-Val-Ala-α-amanitin 6.4 ± 1.9 
33 cyclo[DKP-isoDGR]-PEG-4-Val-Ala-α-amanitin 3.8 ± 0.3 
[a] IC50 values were calculated as the concentration of compound required for 50% 
inhibition of biotinylated vitronectin binding as estimated by GraphPad Prism software. All 
values are the arithmetic mean ± the standard deviation (SD) of triplicate determinations.  
These results indicate that the cyclo[DKP-RGD]-α-amanitin conjugates (42-43) and the 
cyclo[DKP-isoDGR]-α-amanitin conjugates (31-33) retain good binding affinity for the 
integrin αvβ3, notwithstanding the conjugation of the integrin ligand to the linker system 





low-nanomolar range, similar to the original integrin ligands cyclo[DKP-3-RGD] 3 and 
cyclo[DKP-3-isoDGR] 11 (IC50 αvβ3 = 4.5 and 9.2 nM respectively, cf. Table 4).  
3.1.3.2. Cell viability assays 
In order to study the selectivity of the integrin ligand-α-amanitin conjugates targeting 
the αvβ3 receptor, as well as their activity with respect to free α-amanitin, cell viability 
assays were performed in three cell lines expressing different levels of integrin αVβ3: 
human glioblastoma U87 cells line (αVβ3+), human lung carcinoma A549 cell line (αVβ3-) 
and breast adenocarcinoma MDA-MB-468 (αVβ3-). The expression of αVβ3 integrin on 
the cell membrane of the three cell lines was assessed by flow cytometry (Figure 42), 
confirming the information found in the literature for U87 (αVβ3 expressing) and A549 
(αVβ3 non-expressing).172–174 In the case of MDA-MB-468, FACS analyse did not detect 
αVβ3 expression, although the presence of the β3 integrin subunit in this cell line is a 
matter of discussion175,176 and a positive interaction with RGD ligands has been reported 
in the literature.177  
 
Figure 42. Flow cytometry analysis of integrin αVβ3 expression in cancer cell lines. U87-MG: integrin αVβ3 
overexpressed; A549 and MDA-MB 468: integrin αVβ3 negative. 
The cells were treated with different concentrations of the free α-amanitin and the 





assay with triplicated samples. IC50 values representing the concentration of compound 
required for 50% inhibition of cell viability were calculated from the viability curves 
using GraphPad Prism and are shown in Table 6.  
Table 6. Evaluation of anti-proliferative activity of integrin ligand-α-amanitin conjugates 42-43, 31-33 
in U-87, MDA-MB-468 and A549 




























165 ± 4.0 66 ± 24.1 720 ± 98.1 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of cell viability. All 
cell lines were treated with different concentrations of α-amanitin and compounds 42-43, 31-33 for 96 hours. The 
samples were measured in triplicates. [b] Average values from three replicates. [c] n.d.: The IC50 could not be 
determined. 
The cyclo[DKP-isoDGR]-α-amanitin conjugate bearing the lysosomally cleavable Val-Ala 
linker 32 showed an enhanced cytotoxicity compared to the free α-amanitin in the αVβ3 
expressing U87 cell line, as well as in the αVβ3 non-expressing A549 and MDA-MB-468 
cell lines (2.4-3.1 times more potent cf. entry 5 and 1 in Table 6). Conversely, cyclo[DKP-
RGD]-Val-Ala-α-amanitin (43) the RGD analog of 32, resulted less toxic than α-amanitin 
in the three cell lines, which indicates an influence of the isoDGR sequence in the 
efficacy of the conjugates. In the case of the cyclo[DKP-isoDGR]-PEG-4-Val-Ala-PAB-α-
amanitin 33, the cytotoxic activity was slightly higher compared to free α-amanitin in 
U87 (αVβ3+) and MDA-MB-468 (αVβ3-) cell lines (2.1-2.8 times more, cf. entry 6 and 1 in 
Table 6) but it turned out to be less potent than the free drug in A549 (αVβ3-) cell line 





The uncleavable conjugates cyclo[DKP-RGD]-uncleavable-α-amanitin (42) and 
cyclo[DKP-isoDGR]-uncleavable-α-amanitin (31) were less cytotoxic than α-amanitin and 
the conjugates bearing the cleavable linker Val-Ala (43, 32, 33) in the three cell lines. 
This can be attributed to a more efficient drug release mechanism displayed by the 
dipeptide cleavable linker and the self immolative moiety. 
In summary, the results of the antiproliferative assays revealed that the use of dipeptide 
cleavable linkers can improve the activity of the α-amanitin conjugates in comparison to 
the “uncleavable” systems, as in the case of conjugates 43, 32 and 33. It was also 
observed that the cleavable conjugates 32 and 33, containing the isoDGR motif, 
afforded better cytotoxic activity than the cleavable RGD conjugate 43, showing also a 
modest improvement compared to the activity the free α-amanitin. Nevertheless, a 
selective cytotoxicity of the integrin ligand-α-amanitin conjugates towards the αvβ3-
expressing cell line U87 was not observed. 
With the aim of determining if the cytotoxicity of the cyclo[DKP-isoDGR]-α-amanitin 
conjugates 32 and 33 was associated to an integrin-mediated binding and 
internalization process, a competition experiment178 was performed on U87 (αVβ3+, 
αVβ5+, αVβ6-, α5β1+) and MDA-MB-468 (αVβ3-, αVβ5+, αVβ6+, α5β1-)173,174 cell lines, testing 
the antiproliferative activity of the conjugates in the presence of a 50-fold excess of the 
integrin ligand Cilengitide (cyclo[RGDf-(NMe)V], see also Chapter 2). Indeed, if the 
release of α-amanitin occurs upon integrin-mediated endocytosis, a drop in the activity 
of the conjugates would be expected when blocking the cell surface integrins with the 
competitor Cilengitide. The results of this experiment are shown in the Table 7. 
Table 7. Competition experiment of conjugates 10 and 11 in the presence of a 50-fold excess of 




(αVβ3 +, αVβ5 +, 
αVβ6 -, α5β1 +) 
MDA-MB-468 
(αVβ3 -, αVβ5 +, 
αVβ6 +, α5β1 -) 
1 
Cyclo[DKP-isoDGR]-Val-Ala-α-amanitin 32 
Compound 32 + 50-fold excess of Cilengitide 
107 ± 26.8 
106 ± 11.6 
47 ± 21.1 
259 ± 55.2 





Compound 33 + 50-fold excess of Cilengitide 143 ± 59.3 340 ± 210.3 
[a] IC50 values were calculated as the concentration of compound required for 50% inhibition of cell viability. Both 
cell lines were treated with different concentrations compounds 10 and 11 in the presence of a 50-fold excess of 
Cilengitide for 96 hours. The samples were measured in triplicates.  
In the case of U87 cell line, the activity of the conjugate 32 was not altered with the 
excess of Cilengitide (Table 7, entry 1), whereas the conjugate 33 registered a modest 
decrease of its cytotoxic activity: IC50 value increased from 91 nM to 143 nM with 
excess of Cilengitide (Table 7, entry 2). In the MDA-MB-468 cell line, the loss of activity 
was more pronounced for both conjugates: in presence of Cilengitide the IC50 of 
conjugate 32 increased from 47 nM to 259 nM and the IC50 of conjugate 33 increased 
from 65 nM to 340 nM (Table 7, entry 2).  
The results from the competition experiment showed no correlation between the 
expression of integrin αVβ3 and the cytotoxicity of the isoDGR- α-amanitin conjugates 32 
and 33. Nevertheless, since the cell lines used overexpress different integrins (α5β1 in 
U87, αVβ6 in MDA-MB-468, and αVβ5 in both), the increase of the IC50 values of 
conjugates 32 and 33 (up to 5.5 times) may be caused by the blocking of other integrins 
with excess of Cilengitide, which binds efficiently integrin αVβ3 (IC50 = 0.6 nM) but also 
αVβ5 (IC50 = 8.4 nM), α5β1 (IC50 = 14.9 nM)103 and αVβ6 (IC50 = 82.8 nM).179 
3.1.4. Conclusions 
Three cyclo[DKP-isoDGR]-α-amanitin conjugates 31-33 were synthesized by joining the 
functionalized cyclo[DKP-isoDGR]-CH2NH2 integrin ligand 14 to α-amanitin via cleavable 
and uncleavable linkers and different spacers. The conjugates were tested in a 
competitive binding assay, retaining good binding affinity for the purified αvβ3 receptor 
in the low nanomolar range as the free ligand cyclo[DKP-3-isoDGR] 11 and the RGD-α-
amanitin conjugates 42 and 43.  
The cell viability assays performed on U87 (αVβ3+), A549 (αVβ3-) and MDA-MB-468 
(αVβ3-) cancer cell lines showed that the conjugates bearing the lysosomally cleavable 
linker Val-Ala were more potent than the “uncleavable” conjugates on the three cell 
lines. Furthermore, cyclo[DKP-isoDGR]-α-amanitin conjugates 32 and 33 displayed a 
better cytotoxic activity than the RGD cleavable conjugate 43 and were found slightly 





However, contrary to what expected from the binding affinity tests, it was not observed 
a correlation between the cytotoxicity of the conjugates and the expression of integrin 
αVβ3. 
The competition experiments carried out with the isoDGR conjugates 32 and 33 in U87 
(αVβ3+, αVβ5+, αVβ6-, α5β1+) and MDA-MB-468 (αVβ3-, αVβ5+, αVβ6+, α5β1-) in presence of 
50-fold excess of the integrin binder Cilengitide, showed a more pronounced effect of 
the integrin blocking when using the αVβ3-non expressing MDA-MB-468 cell line (IC50 of 
conjugates increased up to 5.5-fold). Since Cilengitide is known to strongly bind not only 
αVβ3, but also αVβ5, αVβ6, and α5β1, these results suggest that the internalization of the 
cyclo[DKP-isoDGR]-α-amanitin conjugates 32 and 33 is possibly mediated by other 





















3.2. Synthesis and biological evaluation of isoDGR-MMAE and isoDGR-
MMAF conjugates 
3.2.1. Monomethyl auristatin E and F 
Monomethyl auristatin E and monomethyl auristatin F (Figure 43) are synthetic analogs 
of dolastatin 10, a natural pseudopeptide isolated from the sea hare Dolabella 
auricularia.180 Dolastatin 10 is highly cytotoxic at very low concentrations (average IC50 < 
1 nM), acting as a potent inhibitor of tubulin polymerization leading to the arrest of cell 
cycle at G2/M phase and cell death.181,182  
 
Figure 43. Dolabella auricularia and chemical structures of dolastatin 10 derivatives monomethyl 
auristatin E and monomethyl auristatin F 
MMAE and MMAF were developed by Seattle Genetics for its use as payloads in 
ADCs.183,184 MMAE is the cytotoxic agent of the FDA approved Adcetris®, where it is 
linked to an anti-CD30 mAb via the protease cleavable Val-Cit dipeptide linker with 
average DAR of 4.185 Due to its high cytotoxicity (IC50 ≈ 1 nM in pancreatic cell lines)186 
MMAE has been used in conjugation with several targeting agents besides monoclonal 
antibodies, for example: aptamers,187 HLIPS,188 and small ligands.140,189,190  
Differently from MMAE, free MMAF possesses a carboxylic acid at the C- terminus that 
is charged at physiological pH, thus increasing the hydrophilicity and limiting the cell 
permeability of the drug. Nevertheless, MMAF is designed to display a high cytotoxicity 
when delivered inside the tumor cells in conjugation to a monoclonal antibody. This 
feature was demonstrated by Doronina and co-workers, who studied the cytotoxic 





increase of the cytotoxicity of the conjugates (2200-fold more potent) compared to the 
free drug in vitro and in vivo.184 Further studies carried out by the same group, 
compared the activity of cAC10vc-MMAF conjugate with its MMAE analogs in CD30 
lymphoma cell lines. While free MMAE displayed 50-200-fold higher activity than 
MMAF, the cAC10vc-MMAF conjugate was up to 3-fold times more potent that 
cAC10vc-MMAE in CD30 positive cell lines, confirming the efficacy of MMAF as a 
payload for targeted therapy.191  
These studies also proved the importance of the protease cleavable dipeptide linker 
Val-Cit for the effective intracellular delivery, lysosomal cleavage and drug release since 
both MMAE and MMAF, execute their mechanism of action in the cytosol.191,192 In 
addition, their physicochemical properties have an influence in the killing efficacy: cell-
permeable MMAE is able to diffuse through neighbor cells, extending its toxic activity 
(bystander-killing effect)39,40 while MMAF is retained inside the cell due to its poor 
membrane permeability, resulting in increased drug accumulation.193 
3.2.2. Synthesis of cyclo[DKP-isoDGR]-MMAE and cyclo[DKP-isoDGR]-MMAF conjugates 
The properties of MMAE and MMAF, and the results from the investigations previously 
cited, raised our interest and we decided to evaluate the efficacy of SMDCs containing 
MMAE or MMAF and the integrin ligand cyclo[DKP-isoDGR]-CH2NH2 14. For this, we 
planned to synthesize two cyclo[DKP-isoDGR]-MMAE and two cyclo[DKP-isoDGR]-MMAF 
conjugates (Figure 43), in collaboration with the University of Milan, by connecting the 
isoDGR ligand 14 containing a PEG-4 spacer to MMAE or MMAF via the lysosomally 






Figure 44. Structure of cyclo[DKP-isoDGR]-MMAE and cyclo[DKP-isoDGR]-MMAF conjugates  
The preparation of the isoDGR ligand (41) containing the PEG spacer, was carried out as 
indicated in Scheme 6.194,195 Commercial tetraethylenglycol was activated with 0.2 
equivalents of p-toluenesulfonyl chloride (to avoid a double substitution) and NaOH in 
THF to obtain PEG-4-OTs 50-a (96% yield). The tosyl group was then substituted using 
sodium azide as a nucleophilic agent, giving the PEG-4-N3 50-b (70% yield). The next 
step was the alkylation of 50-b with bromoacetic acid and excess of NaH to give the 14-
azido-3,6,9,12-tetraoxatetradecanoic acid 51 (73% yield), which was activated with 
EDC.HCl and NHS to obtain intermediate 40 (99% yield) that was coupled to the ligand 
cyclo[DKP-isoDGR]-CH2NH2 14, via pH-controlled reaction (pH 7.3-7.6) in PBS pH 






Scheme 6. Synthesis of cyclo[DKP-isoDGR]-CH2NH-PEG-4-N3 (41). a) TosCl, NaOH, THF, 0° C, 2 h, Y: 96%; 
b) NaN3, MeCN, reflux, overnight, Y: 70%; c) NaH, THF, 0°C to rt. 4 h, Y: 73%; d) EDC.HCl., NHS, DCM, rt. 
overnight, Y: 99%; e) cyclo[DKP-isoDGR]-CH2-NH2 (14), PBS/MeCN 1:1, pH 7.3-7.6, rt. overnight, Y: 65%. 
The protease cleavable linker Val-Ala containing the p-aminobenzyl alcohol (PABA) self-
immolative spacer was prepared following the procedure of Kratz and coworkers,196 as 
described in Scheme 7.  The peptidic synthesis was carried out in solution, allowing to 
obtain the linker in grams scale. Commercial Fmoc-Val was activated with NHS and DCC 
(1:1) in THF and then coupled to alanine (free amino acid) using NaHCO3 as a base in a 
mixture water/THF/diethyl to obtain Fmoc-Val-Ala-OH (52) with 74% yield. P-
aminobenzyl alcohol reacted with the dipeptide 52 in a mixture of DCM/MeOH 2:1, 
using EEDQ as coupling agent to avoid racemization, giving Fmoc-Val-Ala-PABOH 53 
(58%). Finally, the hydroxy group of 53 was activated with p-nitrophenyl chloroformate 
in THF, using pyridine as HCl scavenger, to afford the activated linker Fmoc-Val-PAB-PNP 
54 with 62% yield. 
 
Scheme 7. Synthesis of Val-Ala-PAB-PNP 54. a) DCC, NHS, THF, 0°C to rt. overnight; b) Alanine, NaHCO3, 
THF/diethyl ether/water 1:1:1, rt., 4 days; c) p-aminobenzyl alcohol, EEDQ, DCM/MeOH 2:1, rt. 48 h; d) 
p-nitrophenyl chloroformate, pyridine, THF, 0°C to rt., 4h. 
The conjugates bearing the lysosomally cleavable linker Val-Ala were prepared as 
described in the Scheme 6. The Fmoc-protected Val-Ala-PAB-PNP linker (54) was 





and a catalytic amount of HATU, giving Val-Ala-PABC-MMAE/MMAF (55 or 56) after 
removal of the Fmoc group (62-65% yield over 2 steps). The intermediates were reacted 
with 4-pentynoic acid activated as NHS ester (39) to obtain 4-pentynoic acid-Val-Ala-
PABC-MMAE/MMAF (57 or 58). Finally, a copper catalyzed alkyne-azide cycloaddition 
(CuAAC) between these intermediates and cyclo[DKP-isoDGR]-CH2NH-PEG-4-N3 (41), 
followed by HPLC purification and freeze-drying form H2O/ACN afforded the cleavable 
conjugates cyclo[DKP-isoDGR]-PEG-4-Val-Ala-PABC-MMAE/MMAF 46 and 47 (yield: 66 
and 42% respectively). 
 
Scheme 8. Synthesis of lysosomally cleavable cyclo[DKP-isoDGR]-MMAE and cyclo[DKP-isoDGR]-MMAF 
conjugates. a) MMAE or MMAF, DIPEA, HOAt, DMF, rt., overnight; b) piperidine, DMF, rt., 2h; c) 4-
pentynoic acid-NHS activated (39), DIPEA, DMF, rt., overnight; d) cyclo[DKP-isoDGR]-CH2NH2-PEG-4-N3 
(41), sodium ascorbate, CuSO4·5H2O, H2O:DMF 1/1, rt., overnight. 
The “uncleavable” conjugates 48 and 49 were synthetized as described in the Scheme 7. 
The commercial MMAE or MMAF reacted directly with 4-pentynoic acid-NHS ester (39) 
to give 4-pentynoic acid-MMAE/MMAF (59 or 60) in good yields (69-73%). These 
intermediates underwent a copper catalyzed alkyne-azide cycloaddition (CuAAC) with 
the azide functionalized ligand 41 to obtain the conjugates cyclo[DKP-isoDGR]-PEG-4-






Scheme 9. Synthesis of “uncleavable” cyclo[DKP-isoDGR]-MMAE and cyclo[DKP-isoDGR]-MMAF 
conjugates. a) 4-pentynoic acid-NHS activated (39), DIPEA, DMF, rt., overnight; b) cyclo[DKP-isoDGR]-
CH2NH2-PEG-4-N3 (41), sodium ascorbate, CuSO4·5H2O, H2O:DMF 1/1, rt., overnight. 
During the synthesis of the conjugates, the formation of side products containing the 
drug connected to the linker and the PEG spacer but not containing the integrin ligand 
was detected. This was originated by the contamination of ligand 41 by hydrolyzed 
COOH-PEG-4-N3 51, which reacted via CuAAC reaction with the intermediates 
containing the pentynoic moiety. This contamination could be avoided reducing the 
flow from 15 mL/min to 9 mL/min during the HPLC purification of cyclo[DKP-isoDGR]-
CH2NH2-PEG-4-N3 (41), improving in this way the separation from the hydrolysis 
product. The side products of the click reaction between 41 and the MMAE 
intermediates 57 and 59, were isolated to be used as a control for the targeting activity 
in the cell viability assays (61 and 62, Figure 45). 
 





3.2.3. In vitro studies and discussion 
3.2.3.1. Binding affinity assays 
The conjugates isoDGR-MMAE and isoDGR-MMAF 46-49 were evaluated for their ability 
to inhibit the binding of biotinylated vitronectin to the purified αvβ3 receptor in a 
competitive binding assay. The immobilized integrin receptor was incubated with 
solutions of the conjugates 46-49 at different concentrations in presence of biotinylated 
vitronectin (1 µg mL-1), then the bound vitronectin was measured. The half-maximal 
inhibitory concentrations (IC50) are presented in the Table 8. 
Table 8. Inhibition of biotinylated vitronectin binding to αvβ3 receptor 
Compound Structure IC50 (nM) [a] αVβ3 
46 c[DKP-isoDGR]-PEG-4-Val-Ala-PABC-MMAE 36.2 ± 0.2 
47 c[DKP-isoDGR]-PEG-4-Val-Ala-PABC-MMAF 43.9 ± 2.1 
48 c[DKP-isoDGR]-PEG-4-MMAE 14.5 ± 0.6 
49 c[DKP-isoDGR]-PEG-4-MMAF 10.7 ± 2.8 
[a] IC50 values were calculated as the concentration of compound required for 50% 
inhibition of biotinylated vitronectin binding as estimated by GraphPad Prism 
software. All values are the arithmetic mean ± the standard deviation (SD) of 
duplicated determinations 
The four conjugates 46-49 retained a good binding affinity for the αvβ3 receptor with 
IC50 values in the nanomolar range. It was observed though, a slight increase of the IC50 
of the conjugates compared to the free ligand cyclo[DKP-3-isoDGR] 11 (αvβ3 IC50 9.2 nM, 
cf. Table 4), differently from what observed for the cleavable isoDGR-α-amanitin 
conjugates. These result suggest that the conformational modifications resulting from 
the conjugation to the linker and the drug might have a moderate effect on the binding 
affinity of the isoDGR ligand to the αvβ3 receptor. 
3.2.3.2. Cell viability assays 
The isoDGR conjugates 46-49, together with their RGD analogs (Figure 45, compounds 
63-66) synthetized by André Dias (University of Milano), were evaluated for their ability 
to selectively target αvβ3-expressing tumor cells in cell viability assays on U87 human 





HT29 (human colon cancer) cell line, which was selected as αVβ3 negative.173 
Compounds 61 and 62, containing the PEG spacer, the linker and MMAE but not the 
integrin ligand, were tested as a negative control for the αvβ3 targeting. 
 
Figure 46. Structure of cyclo[DKP-RGD]-MMAE and cyclo[DKP-RGD]-MMAF conjugates 
U87 and HT29 cells were treated with different concentrations of the free drug MMAE 
or MMAF and the conjugates for 72 hours with or without washout. For the washout 
experiments, the cells were washed after 6 hours of incubation, the media was replaced 
and then the cells were incubated for other 66 hours. This procedure has been 
previously used by our research group,70 intending to simulate the in vivo conditions 
where the administered prodrug is rapidly cleared from the tumor extracellular 
environment. In this way the conjugates degraded or unbound to the integrin receptors 
are removed from the medium, minimizing the effect of metabolites produced by 
extracellular cleavage of the linker. The cell viability was quantified by MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. The IC50 values presented 






Table 9. Antiproliferative activity of RGD-MMAE and isoDGR-MMAE conjugates in human glioblastoma 
U87-MG cell line after 72 h incubation with and without washout after 6h, and in human colon cancer 
HT29 after 72 h incubation without washout.  
Entry Structure 
IC50 (nM) U87-MG (αvβ3+) [a] 
IC50 (nM) HT29 
(αVβ3 -, αVβ5+, 
αVβ6+) [a] 
WO 6h + 66h 72h no WO 72h no WO 
1 MMAE (44) 0.144 ± 0.06 0.076 ± 0.08 0.030 ± 0.04 








83.54 ± 0.04 11.5 ± 0.13 27.71 ± 0.04 
5 COOH-PEG-4-MMAE (62) n.d. n.d. >10000 
6 c[DKP-RGD]-PEG-4-MMAE (65) 738.8 ± 34.3 1228 ± 0.21 464.2 ± 0.08 
7 c[DKP-isoDGR]-PEG-4-MMAE (48) n.d. [b] 685.5 382 ± 0.08 
[a]Cells were treated with different concentrations of free MMAE, conjugates 46, 48, 63, 65 and compounds 
61 and 62 for 72 hours, with washout (WO) after 6h and without washout (no WO). IC50 values were 
calculated as the concentration of compound required for 50% inhibition of cell viability. [b] IC50 could not be 
determined.  
As can be appreciated in Table 9, the MMAE conjugates 63 and 46 bearing the cleavable 
Val-Ala linker displayed nanomolar IC50 values in the experiment at 72 hours incubation 
without washout in U87 cell line (IC50 = 38.99 and 11.5 nM, entry 3 and 4 in Table 9), 
proving to be more cytotoxic than the “uncleavable” conjugates 65 and 48 and the non-
targeting compound 61, even if much less potent (150-500 times less) than free MMAE 
that displays picomolar activity. In particular, the conjugate cyclo[DKP-isoDGR]-PEG-4-
Val-Ala-PABC-MMAE (46) resulted 60 fold-more toxic than uncleavable cyclo[DKP-
isoDGR]-PEG-4-MMAE (48), 6.6-fold more toxic than the non-targeting COOH-PEG-4-
Val-Ala-PABC-MMAE (61) and 3.4-times more potent than its RGD analog cyclo[DKP-
RGD]-PEG-4-MMAE (63).  
In the experiment with washout after 6 hours, both MMAE and the conjugates were, as 





reduced cytotoxicity with respect to free MMAE, being the “uncleavable” conjugates 65 
and 48 the least cytotoxic. In particular, the loss of activity of conjugates 63 and 46, 
containing the cleavable linker, compared to free MMAE is increased by a factor of 4-5 
in the experiment with washout, as can be calculated comparing the ratio 63/MMAE 
and 46/MMAE in both experiments (cf. entry 3 and 4 with entry 1 in Table 9). These 
results suggest that the activity observed for the MMAE conjugates is not completely 
consistent with an αvβ3 integrin-mediated internalization process. In fact, the 
differences observed in both experiments, notably in the cytotoxicity of the cleavable 
conjugates 63 and 46, could be attributed to the early release and diffusion of MMAE 
after extracellular cleavage of the Val-Ala linker by serine proteases present in the 
cellular environment or by cathepsin B released upon cell dead and degradation after 
72 hours.42,197,198  
The antiproliferative activity of the MMAE conjugates in HT29 (αVβ3 negative) cell line, 
indicate a loss of potency respect to the unconjugated MMAE, similar to what observed 
in the experiment with U87 (αVβ3 positive) cell line, as well as an increase in the 
cytotoxicity of the conjugates compared to the non-targeting compounds (61 and 62), 
up to 10.7-fold times in the case of the cleavable MMAE conjugate cyclo[DKP-isoDGR]-
PEG-4-Val-Ala-PABC-MMAE 46 (cf. entry 4 with entry 2 in Table 9).  Interestingly,  for 
the cleavable MMAE conjugates 46 and 63, the loss in the cytotoxicity compared to free 
MMAE was more pronounced in HT29 than in U87 cell line: cyclo[DKP-RGD]-PEG-4-Val-
Ala-PABC-MMAE (63) was 500 less toxic than MMAE in U87 (αVβ3+) and 1700 times less 
toxic than MMAE in HT29 (αVβ3-) cell line (cf. entry 3 with entry 1 in Table 9), whereas 
cyclo[DKP-isoDGR]-PEG-4-Val-Ala-PABC-MMAE (46) was 150 times less toxic than MMAE 
in U87 (αVβ3+) and 920 times less toxic than MMAE in HT29 (αVβ3-) (cf. entry 4 with 
entry 1 in Table 9). These results show a moderate targeting index, TI = 6.1 and 3.3 for 
MMAE cleavable conjugates 46 and 63 respectively (Table 10), suggesting that the 
activity of the conjugates is possibly associated to other integrins different from αVβ3 in 























11.5 ± 0.13 27.71 ± 0.04 2.4 6.1 
[a]IC50 values were calculated as the concentration of compound required for 50% inhibition of cell viability. [b] 
IC50 could not be determined; [b] Selectivity (S): IC50 (αvβ3-) / IC50 (αvβ3+); [c] Targeting index (TI): S conjugate / S free 
MMAE 
The antiproliferative activity of the MMAF conjugates in U87 and HT29 cell line is shown 
in Table 11. In the experiment with U87 cell line at 72 hours incubation without 
washout, free MMAF was, as expected, less toxic than MMAE due to the charged 
carboxylic group that limits its capacity to diffuse through the cell membrane.199,200 The 
conjugates 64 and 47, bearing the cleavable Val-Ala linker, presented cytotoxic activity 
values in the sub-micromolar range, 1.7-3.4 times less potent than the activity 
registered for MMAF (cf. entry 2 and 3 with entry 1 in Table 11). Also, like in the 
previous experiments, the “uncleavable” conjugates proved the least cytotoxic, with 
IC50 values > 10 µM in the case of cyclo[DKP-RGD]-PEG-4-MMAF (66). The experiment 
with washout after 6 hours was also run but, in this case, no cytotoxic activity was 
determined for free MMAF or the MMAF conjugates, with exception of cyclo[DKP-
isoDGR]-PEG-4-Val-Ala-PABC-MMAF (47) that displayed micromolar cytotoxicity (IC50 = 
3358 nM, entry 3 in Table 11). These data indicate that the conjugation to cyclo[DKP-
RGD] or cyclo[DKP-isoDGR] integrin ligands does not significantly improve the cellular 
uptake of MMAF, and the activity displayed by the cleavable MMAF conjugates is mainly 







Table 11. Antiproliferative activity of RGD-MMAF and isoDGR-MMAF conjugates in human glioblastoma 
U87-MG cell line after 72 h incubation with and without washout after 6h 
Entry Structure 
IC50 (nM) U87-MG (αvβ3+) [a] 
IC50 (nM) 
HT29 (αVβ3 -, 
αVβ5+, αVβ6+) 
[a] 
WO 6h + 66h 72h no WO 72h no WO 
1 MMAF (45) n.d.[b] 94.4 ± 0.06 52.16 ± 0.06 
2 c[DKP-RGD]-PEG-4-Val-Ala-PABC-MMAF (64) n.d.[b] 331.9 ± 0.10 719.2 ± 0.07 
3 c[DKP-isoDGR]-PEG-4-Val-Ala-PABC-MMAF (47) 3358 165.9 ± 0.06 511 ± 0.04 
4 c[DKP-RGD]-PEG-4-MMAF (66) n.d.[b] > 10000 >10000 
5 c[DKP-isoDGR]-PEG-4-MMAF (49) n.d. 763.7 ± 0.08 1197 ± 0.07 
[a]Cells were treated with different concentrations of free MMAF, conjugates 47, 49, 64, and 67 for 72 hours, with 
washout (WO) after 6h and without washout (no WO). IC50 values were calculated as the concentration of compound 
required for 50% inhibition of cell viability. [b]Non-determined. 
In the experiment with HT29 (αVβ3-) cell line, MMAF conjugates presented a loss of 
potency regarding the activity of free drug MMAF more pronounced that in the 
experiment with U87 (αVβ3-) cell line: cyclo[DKP-RGD]-PEG-4-Val-Ala-PABC-MMAF (64) 
was 3.5 less toxic than MMAF in U87 (αVβ3+) and 14 times less toxic than MMAF in 
HT29 (αVβ3-) (cf. entry 2 with entry 1 in Table 10), cyclo[DKP-isoDGR]-PEG-4-Val-Ala-
PABC-MMAF (47) was 1.7 times less toxic than MMAF in U87 (αVβ3+) and 10 times less 
toxic than MMAF in HT29 (αVβ3-) (cf. entry 3 with entry 1 in Table 10), and cyclo[DKP-
isoDGR]-PEG-4-MMAF (49) was 8 times less toxic than MMAF in U87 (αVβ3+) and 23 
times less toxic than MMAF in HT29 (αVβ3-) (cf. entry 5 with entry 1 in Table 10). These 
results indicate once more, a moderate targeting index, TI = 5.6 and 3.9 for MMAF 
cleavable conjugates 47 and 64 respectively (Table 12). Apparently, the activity of the 
MMAF conjugates could be associated to other integrins different from αVβ3, present in 






















165.9 ± 0.06 511 ± 0.04 3.1 5.6 
[a]IC50 values were calculated as the concentration of compound required for 50% inhibition of cell viability. [b] 




A small library of four SMDC containing the functionalized integrin ligand cyclo[DKP-
isoDGR]-CH2NH2 (14) and the dolastatin derivatives MMAE or MMAF as payloads has 
been synthetized. The conjugates were obtained via copper (I) catalyzed alkyne-azide 
cycloaddition (CuAAC) between the integrin ligand functionalized with a PEG4-azide 
spacer and an alkyne moiety directly attached to MMAE or MMAF (conjugates 48 and 
49 respectively) or to the dipeptide Val-Ala linker bearing the PABC self-immolative 
spacer connected to MMAE or MMAF (conjugates 46 and 47). 
The four isoDGR conjugates were tested in a competitive binding assay, retaining good 
binding affinity for the purified αvβ3 receptor in the nanomolar range, although a slight 
increase in the αvβ3 IC50 was detected for the cleavable conjugates 46 and 47 in contrast 
to the free integrin ligand cyclo[DKP-3-isoDGR] 11. This revealed a moderate effect of 
the conjugation in the binding affinity towards the αvβ3 receptor non-observed before 
for the isoDGR conjugates. 
The antiproliferative activity of the isoDGR-MMAE and isoDGR-MMAF conjugates (46-
49), and their RGD analogs (63-66) was evaluated in a first set of cell viability assays 
carried out in U87 (αVβ3 expressing) cell line at 72 hours incubation time with and 





general, a drop of cytotoxicity for the conjugates compared to the free MMAE or 
MMAF, especially for the uncleavable conjugates. The conjugates bearing the Val-Ala 
cleavable linker displayed better cytotoxic activity values, particularly the cleavable 
isoDGR-MMAE conjugate 46 that resulted 6.6-fold more toxic than the non-targeting 
compound COOH-PEG-4-Val-Ala-PABC-MMAE 61 and 3.4-times more toxic than its RGD 
analog cyclo[DKP-RGD]-PEG-4-MMAE 63 in the experiment without washout. 
Nevertheless, the washout experiment involving the MMAF conjugates revealed that 
the conjugation to the integrin ligands has a poor contribution to the cellular uptake of 
MMAF. 
The cell viability assays carried out in HT29 (αVβ3-, αVβ5+, αVβ6+) cell line with 72 hours 
incubation time, confirmed the loss of cytotoxicity of the conjugates compared to free 
MMAE and MMAF, nonetheless, this loss of potency was more pronounced in the αVβ3-
negative cell line HT29. In fact, the targeting index obtained for the cleavable MMAE 
and MMAF conjugates (6.1-3.3 and 5.6-3.9 respectively) indicate a moderate selectivity 
towards the αVβ3 receptor, even though the activity of the conjugates might also be 
governed by other integrins different from αVβ3 (e.g. αVβ5 in U87 and αVβ5, αVβ6 in 
HT29). 
Overall, the results from the in vitro tests demonstrate that despite the high binding 
affinity towards the αVβ3 receptor, the conjugates are not necessarily internalized by 
integrin-mediated endocytosis. This becomes clearer in the case of the MMAF 
conjugates, whose cytotoxic activity is similar to the free MMAF, which is known to 
poorly penetrate the cell membrane due to its charged phenylalanine residue. In the 
case of the MMAE conjugates, the cytotoxic activity is boosted by the picomolar 
potency of the drug and its ability to diffuse through the cell membrane once it is 
released upon extracellular cleavage, as reported in the literature.42,197,198 In effect, the 
conjugates containing the protease cleavable linker Val-Ala display higher cytotoxicity 
than the uncleavable conjugates because they allow the effective release of the payload 
when cleaved by extracellular proteases. Importantly, the increased cytotoxicity 
registered for the cleavable MMAE conjugates 46 and 63 compared to the non-





αVβ6+) cell lines suggests, if not an αVβ3 integrin-mediated internalization, a possible 







Material and methods 
All manipulations requiring anhydrous conditions were carried out in flame-dried 
glassware, with magnetic stirring and under a nitrogen atmosphere. All commercially 
available reagents were used as received. Anhydrous solvents were purchased from 
commercial sources and withdrawn from the container by syringe, under a slight 
positive pressure of nitrogen. The reactions were monitored by analytical thin-layer 
chromatography (TLC) using Macherey-Nagel 0.20 mm silica gel 60 with fluorescent 
indicator pre-coated polyester sheets (40 × 80 mm). Visualization was accomplished by 
irradiation with a UV lamp and/or staining with Cerium/Molibdate reagent, ninhydrin or 
cinnamaldehyde. Flash column chromatography was performed according to the 
method of Still and co-workers201 using Chromagel 60 ACC (40-63 µm) silica gel. Proton 
NMR spectra were recorded on a spectrometer operating at 400.16 MHz. Proton 
chemical shifts are reported in ppm (δ) with the solvent reference relative to 
tetramethylsilane (TMS) employed as the internal standard (D2O δ = 4.79 ppm). The 
following abbreviations are used to describe spin multiplicity: s = singlet, d = doublet, t = 
triplet, q = quartet, m = multiplet, bs = broad signal, dd = doublet of doublet, ddd = 
doublet of doublet of doublet, ddt = doublet of doublet of triplet, td= triplet of doublet. 
Carbon NMR spectra were recorded on a spectrometer operating at 100.63 MHz, with 
complete proton decoupling. Carbon chemical shifts are reported in ppm (δ) relative to 
TMS with the respective solvent resonance as the internal standard. ESI-MS spectra 
were recorded on the ion trap mass spectrometer Finnigan LCQ Advantage or Micro 
Waters Q-Tof (ESI source) and on Thermo Fisher linear ion trap LTQ XL mass 
spectrometer. 
HPLC purifications and HPLC traces of final products were performed on Dionex 
Ultimate 3000 equipped with Dionex RS Variable Wavelenght Detector (column: Atlantis 
Prep T3 OBDTM 5 µm 19 × 100 mm; flow 15 mL/min unless stated otherwise). The crude 





quantity of DMF to the aqueous solution if the compound was insoluble (an ultrasonic 
bath was used to assist the dissolution). The solution obtained was filtered 
(polypropylene, 0.45 μm, 13 mm ø, PK/100) and injected in the HPLC, affording purified 
products. Purity analyses were carried on a Dionex Ultimate 3000 instrument equipped 
with a Dionex RS Variable Wavelenght detector (column: Atlantis® Prep T3 OBDTM 5 
μm 19 × 100 mm). 1 mg of analyte was dissolved in 1 mL of H2O and was injected using 
the same gradient used in the purification step. The analysis of the integrals and the 
relative percentage of purity was performed with the software Cromeleon 6.80 SR11 
Build 3161. Also, preparative HPLC LaPrep∑ equipped with autosampler AS3950 and a 
Phenomenex Luna C-18(2) column, 10 µm, 250 × 21.2 mm, with precolumn at 30 
mL/min flow rate and analytical HPLC performed on Hitachi Chromaster (column oven 
Chromaster 5310, pump Chromaster 5110, autosampler Chromaster 5210, DAD 
Chromaster 5430) equipped with a Phenomenex Luna C-18(2) column, 10 µm, 250 × 4.6 
mm, with precolumn at 1.4 mL/min flow rate were used. 
Freeze-drying: The product was dissolved in water or water/ acetonitrile 1:1 and frozen 
with dry ice. The freeze-drying was carried out at least for 48 h at -50 °C using the 
instrument 5Pascal Lio5P DGT. 
Biological assays 
Solid Phase Receptor Binding Assays 
Recombinant human integrin V 3 (R&D Systems, Minneapolis, MN, USA) was diluted to 
0.5 g/mL in coating buffer containing 20 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM 
MnCl2, 2 mM CaCl2, and 1 mM MgCl2. 100 Microliters of the diluted receptor (100 
L/well) were added to 96-well microtiter plates (Nunc MaxiSorp) and incubated 
overnight at 4 °C. The plates were treated for additional 2 h at room temperature with 
blocking solution (coating buffer plus 1% bovine serum albumin) to block nonspecific 
binding, and washed 2 times with the same solution. Different concentrations (10-5–10-
12 M) of the test compounds in the presence of 1 g/mL biotinylated vitronectin were 
added to the plates, which were shaken for 3 h at room temperature. Vitronectin, 
(Molecular Innovations, Novi, MI, USA) was biotinylated using an EZ-Link Sulfo-NHS-





incubated with shaking for 1 h, at room temperature, with streptavidin-biotinylated 
peroxidase complex (Amersham Biosciences, Uppsala, Sweden). The plates were again 
washed 3 times with blocking solution, and 100 L/well of Substrate Reagent Solution 
(R&D Systems, Minneapolis, MN, USA) were added before shaking in the dark for 30 
min and stopping the reaction with the addition of 50 L/well 2 N H2SO4. Absorbance at 
415 nm was read in a SynergyTM HT Multi-Detection Microplate Reader (BioTek 
Instruments, Inc.). Each data point represents the average of triplicate wells; data 
analysis was carried out by nonlinear regression analysis with GraphPad Prism software. 
Each experiment was repeated in triplicate or duplicate. 
Determination of integrin αVβ3 expression by flow cytometry 
The expression of integrin αVβ3 in U87-MG, A549 and MDA-MB 468 cells was 
determined by flow cytometry on a FACSCalibur device (Becton Dickinson). Before 
staining, cells were fixed with fixation solution (0.5% PFA in PBS). 5 × 105 cells per 
sample were stained in staining medium (PBS, 25 mM HEPES, 3% FCS, 0.02% Na-Azide) 
with an anti-human integrin αVβ3 antibody conjugated to Alexa Fluor 488 (R&D Systems) 
or isotype control conjugated to Alexa Fluor 488 (Thermo Fischer) at a concentration of 
4µg/mL for 45 min at room temperature. Cells were washed with PBS and the mean 
fluorescence intensity was measured for 10.000 gated events. Data were analyzed using 
flow cytometry and associated software (BD Biosciences)  
Cell culture for cell viability assays of integrin ligand-α-amanitin conjugates 
All cell culture reagents were purchased at PAN-Biotech GmbH unless otherwise stated. 
Cell lines were obtained from CLS (U87-MG, MDA-MB 468 and A549). Cell lines were 
authenticated using Multiplex Cell Authentication by Multiplexion (Heidelberg, 
Germany) as described in the literature.202 The SNP profiles matched known profiles or 
were unique. The purity of cell lines was validated using the Multiplex cell 
Contamination Test by Multiplexion (Heidelberg, Germany) as described in the 
literature.203 No Mycoplasma, SMRV or interspecies contamination was detected. U87-
MG, MDA-MB 468 and A549 cells were cultivated continuously for not more than 3 





10% heat inactivated fetus calf serum, L-glutamine and antibiotics. Cell lines were 
maintained at 37°C and 5% CO2 in a high humidity atmosphere. 
 
Cell therapy and viability assays of integrin ligand-α-amanitin conjugates 
Cell viability assays were performed in U87-MG, A549 and MDA-MB 468 cell lines 
according to the following procedure: 2 × 103 cells/well were plated in 96-well black 
clear bottom plates (Perkin Elmer) and incubated overnight. 1:5 serial dilutions of 
compounds 31-33 and 42-43 were prepared in cell culture media. Compounds were 
added to cell culture and incubated for additional 96 h. Starting concentration of 
compounds 31-33 and 42-43 in the wells was 1 × 10-5 M and cell viability was 
determined with the CellTiterGlo 2.0 assay (Promega) in accordance to manufacturer’s 
instructions. Cell viability was calculated in relation to the non-treated controls for each 
cell line. All samples were measured in triplicate. Data analysis was carried out using 
software Graph Pad Prism (Graph Pad Software Inc., La Jolla, CA, USA).  
Competition experiment for conjugates 32 and 33 
The competition experiments were performed in U87-MG and MDA-MB 468 cell lines 
according to the following procedure: 2 × 103 cells/well were plated in 96-well black 
clear bottom plates (Perkin Elmer) and incubated overnight. A solution containing 1 × 
10-4 M of the conjugate (32 or 33) and 5 × 10-3 M of Cilengitide (50-fold excess of ligand 
in comparison to the conjugate) was prepared in the growth medium and 1:5 serial 
dilutions were prepared in cell culture media. The compounds were added to cell 
culture and incubated for 96 h. Starting concentration of the compounds in the wells 
was 0.01 mM whereas that of Cilengitide was 0.5 mM. Cell viability was determined with 
the CellTiterGlo 2.0 assay (Promega) in accordance to manufacturer’s instructions. Cell 
viability was calculated in relation to the non-treated controls for each cell line. All 
samples were measured in triplicate. Data analysis was carried out using software 






Cell therapy and viability assays of integrin ligand-MMAE/MMAF conjugates 
Cell viability assays were performed in U-87 MG glioblastoma and H29 colon 
adenocarcinoma cells obtained from American Type Culture Collection (ATCC, 
Bethesda, MD, USA) were used. Cell viability was quantified by MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. Briefly, cells in EMEM 
supplemented with 10% FBS, 1% L-glutamine and 1% penicillin/streptomycin, were 
seeded in 96-well culture plates (5×104 cells/well) and incubated in a humidified, 37°C, 
5% CO2 atmosphere overnight to allow adherence. The following day cells were treated 
with serial dilutions of each compound starting at 500 nM for MMAE and 5000 nM for 
each one of the conjugates, or 0.1% DMSO as a control, and incubated as described for 
72h. For the washout experiment, cells were washed once, and media replaced after 6h 
of incubation. At the end of treatment, 5 µL of MTT (5 mg/mL in dH2O, Sigma #M5655) 
was added to each well. The cells were incubated for another 2 hours, 100 μL of lysis 
buffer (10% SDS, 10 mM HCl) were added, and then the cells were placed in the 
incubator overnight for the formazan crystal solubilization. Absorbance at 540 nm was 
measured and the growth inhibition ratio was calculated. Blank controls detecting cell-
free media absorbance were performed in parallel. Three experimental replicates were 
used. The half-maximal inhibitory concentration values (IC50) were obtained from 
viability curves using GraphPad Prism 6. The cell viability was expressed as percentage 
relative to the respective control conditions (0.1% of DMSO). 
Synthesis of the DKP-f3 scaffold 
4-((4-methoxy-2,3,6-trimethyl-phenyl-sulfonyl)aminomethyl)benzaldehyde 16 
 
(4-aminomethyl-phenyl)methanol (2.6 g, 19 mmol, 1 eq.) was dissolved in 150 mL of dry 
THF under nitrogen atmosphere, DIPEA (6.5 mL, 38 mmol, 2 eq.) was added and the 
solution was cooled to 0 °C. A solution of 4-methoxy-2,3,6-trimethylbenzene-1-sulfonyl 





mixture was stirred at 0°C for 30 min, then at room temperature overnight. The white 
precipitate formed was separated by filtration over celite and the filtrate was 
concentrated under reduced pressure, re-dissolved in 5 mL of dry DCM (5 mL) and 
sonicated for few minutes until the formation of a white precipitate. The precipitate 
was collected by filtration, washed with cold DCM and cold Et2O and dried under 
vacuum to obtain the 4-((4-methoxy-2,3,6-trimethyl-phenyl-sulfonyl)aminomethyl) 
benzylic alcohol as a pale-yellow powder (4.98 g, 72% yield).  
The protected alcohol (4.8 g, 13.7 mmol, 1 eq.) was dissolved in 150 mL of dry THF 
under nitrogen atmosphere, then activated MnO2 (18 g, 0.2 mol, 15 eq.) was added, 
and the mixture was stirred overnight at room temperature. The suspension was 
filtered over celite and the filtrate was concentrated under reduced pressure to obtain 
16 as a white solid. (4.76 g, 99% yield).  
Rf=0.76 (Hexane/EtOAc 1:1); 1H NMR (400 MHz, acetone-d6) δ 9.96 (s, 1H), 7.75 (d, 2H, 
J = 8.2 Hz), 7.42 (d, 2H, J = 8.1 Hz), 6.92 (t, 1H, J = 6.3 Hz), 6.72 (s, 1H), 4.19 (d, 2H, J = 
6.5 Hz), 3.83 (s, 3H), 2.62 (s, 3H), 2.53 (s, 3H). 
(S)-methyl-3-hydroxy-2-((4-((4-methoxy-2,3,6-trimethyl-phenyl-sulfonamido)methyl) 
benzyl) amino)propanoate 17 
 
To a suspension of L-serine methyl ester hydrochloride (1.0 g, 6.5 mmol, 1.25 eq.) and 
aldehyde 16 (1.8 g, 5.1 mmol, 1 eq.) in 100 mL of dry THF, was added triethylamine (1.1 
mL, 7.6 mmol, 1.5 eq.) under nitrogen atmosphere. Then, NaBH(OAc)3 (3.1 g, 14.3 
mmol, 2.8 eq.) was added in small portions and the mixture was stirred at room 
temperature for 4 h. A saturated solution of NaHCO3 was added to the suspension till 
pH > 7 and it was extracted with EtOAc (3 × 60 mL). The combined organic phases were 
washed with brine (3 × 40 mL), dried over Na2SO4 and concentrated under reduced 
pressure. The crude product was purified by flash chromatography on silica gel (100 % 





Rf=0.56 (EtOAc 100%); 1H NMR (400 MHz, CD2Cl2) δ 7.21 (d, J = 7.9 Hz, 2H), 7.10 (d, J = 
7.9 Hz, 2H), 6.62 (s, 1H), 4.90 (t, J = 6.1 Hz, 1H), 4.02 (d, J = 6.2 Hz, 2H), 3.85 (s, 3H), 3.82 
(d, J = 12.8 Hz, 1H), 3.73 – 3.69 (m, 4H), 3.64 (d, J = 13.2 Hz, 1H), 3.59-3.55 (dd, J = 10.8, 
6.2 Hz, 1H), 3.36 (m, 1H), 2.65 (s, 3H), 2.51 (s, 3H), 2.11 (s, 3H). 
 
(R)-4-(allyloxy)-2-((tert-butoxycarbonyl)amino)-4-oxobutanoic acid 15 
 
Acetyl chloride (10.7 mL, 15 mmol, 4 eq.) was added dropwise to 75 mL of ice-cold allyl 
alcohol. The solution was stirred at 0°C for 15 minutes and at room temperature for 1 
hour, then D-aspartic acid (5 g, 37 mmol, 1 eq.) was added in single portion and the 
suspension was stirred overnight. The mixture was poured into 250 mL of ice-cold Et2O 
and stirred for 1 hour, observing the formation of a white precipitate. The solid was 
collected by filtration and washed with cold Et2O to give allyl aspartic acid hydrochloride 
(6.7 g, 82% yield).  
D-allyl aspartic acid hydrochloride (6.7 g, 32 mmol, 1 eq.) was dissolved in dioxane/water 
1:1 (80 mL) under nitrogen atmosphere, Boc2O (8.3 g, 38 mmol, 1.2 eq.) was added and 
the mixture was cooled to 0 °C. Et3N (13.3 mL, 95 mmol, 3 eq.) was added dropwise and 
the mixture was stirred at room temperature overnight. The solution was diluted in 150 
mL of EtOAc, washed with KHSO4 1 M (3 × 50 mL) and brine (1 × 50 mL), the organic 
phase was dried over Na2SO4 and concentrated under reduced pressure affording the 
product 15 as a colorless oil (5.2 g, 79%). 
(R)-4-allyl-1-((S)-3-methoxy-2-((4-((4-methoxy-2,3,6-trimethylphenylsulfonamido) 






To a solution of 15 (1.2 g, 4.3 mmol, 1.3 eq.) in 15 mL of dry DMF at 0°C, HATU (1.6 g, 
4.3 mmol, 1.3 eq.), HOAt (0.589 mg, 4.3 mmol, 1.3 eq.) and DIPEA (1.2 mL, 6.6 mmol, 
2.0 eq.) were added, and the mixture was stirred for 30 minutes at 0 °C. A solution of 17 
(1.5 g, 3.3 mmol) in DMF (10 mL) was added to the previous mixture and the reaction 
was stirred 1 h at 0°C and then at room temperature for 4 hours. The mixture was 
diluted with EtOAc (150 mL) and washed with KHSO4 1 M (3 × 30 mL), NaHCO3 (2 × 30 
mL) and brine (1 × 30 mL), the organic phase was dried over Na2SO4 and concentrated 
under reduced pressure to give the crude product as a pale-yellow oil (3 g) that was 
used in the next step without further purification. Rf=0.37 (Hexane/EtOAc 1:1) 
OH-(3S-6R)-DKP-f3-COOAllyl 19 
 
Boc-isopeptide 18 (2.3 g, 3.3 mmol, 1 eq.) was Boc-deprotected in a solution of 
CH2Cl2/TFA 2:1 (25 mL), stirring for 2 hours at room temperature. Volatiles were 
removed under reduced pressure by adding toluene (2 x 15 mL) and Et2O (1 x 15 mL) to 
remove the excess of TFA. The corresponding trifluoroacetate salt was dried under 
vacuum and re-dissolved in iPrOH (54 mL). DIPEA (2.3 mL, 13.2 mmol, 4 eq.) was added, 
and the mixture was stirred at room temperature overnight. The solution was 
concentrated under reduced pressure and the residue was purified by flash 
chromatography on silica gel (Hexane/EtOAc, from 70% EtOAc to 100%) affording the 





Rf=0.27 (EtOAc 100%); 1H NMR (400 MHz, CDCl3) δ 7.19 (m, 4H), 6.74 (s, 1H), 6.65 (s, 
1H), 5.95 (m, 1H), 5.39-5.33 (m, 2H), 5.27,  (dq, J = 10.4, 1.3 Hz, 1H), 5.15 (d, J = 15.2 Hz, 
1H), 4.98 (t, J = 6.3 Hz, 1H), 4.64 (dt, J = 5.7, 1.3 Hz, 2H), 4.61 (dd, J = 8.7, 3.6 Hz, 1H),  
4.13 (d, J = 15.5 Hz, 1H), 4.04 (d, J = 6.3, 2H), 3.99 (d, J = 11.8 Hz, 1H), 3.88 – 3.84 (m, 
4H), 3.79 (t, J = 2.6 Hz, 1H), 3.23 (dd, J = 17.4, 3.7 Hz, 1H), 2.76 (dd, J = 17.6, 8.3 Hz, 1H), 
2.67 (s, 3H), 2.56 (s, 3H), 2.16 (s, 3H). 
N3-(3S, 6R)-DKP-f3-COOAllyl 20 
 
OH-(3S, 6R)-DKP-f3-COOAllyl 19 (1.68 g, 2.9 mmol, 1 eq.) was dissolved in 50 mL of a 
mixture of CH2Cl2/toluene 4:6 under nitrogen atmosphere. The mixture was cooled to -
20°C and triphenylphosphine (1.0 g, 3.8 mmol, 1.3 eq.) was added. Once the dissolution 
was completed, hydrazoic acid (1 M in toluene, 19 mL, 19 mmol, 6.5 eq.) was added, 
followed by dropwise addition of DIAD (0.8 mL, 4.1 mmol, 1.4 eq.). The reaction was 
stirred at -20 °C for 5 hours, then the mixture was directly purified (without evaporating 
the solvent) by flash chromatography (EtOAc/Hexane from 1:1 to 70% EtOAc) affording 
the product 20 as a white foam (1.15 g, 66% yield). 
Rf=0.6 (EtOAc/Hexane 8:2); 1H NMR (400 MHz, CDCl3) δ 7.18 (s, 4H), 6.76 (s, 1H), 6.59 
(s, 1H), 5.91 (ddt, J = 16.4, 11.1, 5.8 Hz, 1H), 5.34 (d, J = 18.1, 1H), 5.27 (d, J = 10.4, 1H), 
5.09 (d, J = 15.1 Hz, 1H), 4.64 (d, J = 5.8 Hz, 2H), 4.60 (dd, J = 9.1, 3.1 Hz, 1H), 4.19 (d, J = 
15.1 Hz, 1H), 4.05 (s, 2H), 3.90 – 3.83 (m, 6H), 3.63 (dd, J = 12.4, 2.9 Hz, 1H), 3.28 (dd, J 







N3-(3S, 6R)-DKP-f3-COOAllyl 20 (1.56 g, 2.6 mmol, 1 eq.) was dissolved in 64 mL of THF 
under nitrogen atmosphere and cooled down to -20 °C. Trimethylphosphine (1 M 
solution in THF, 6.5 mL, 6.5 mmol, 2.5 eq.) and Boc-ON (1.6 g, 6.5 mmol, 2.5 eq.) were 
sequentially added and the reaction was stirred at room temperature for 3h. The 
mixture was diluted in 300 mL of CH2Cl2 and the organic phase was washed with water 
(3×100 mL) and brine (1×100 mL), dried over Na2SO4 and concentrated under reduced 
pressure. The crude residue was purified by flash chromatography on silica gel 
(CH2Cl2/MeOH from 100% CH2Cl2 to 9:1) affording the product 21 as a white foam (1.55 
g, 88% yield).  
Rf=0.24 (CH2Cl2/MeOH 97:3); 1H NMR (400 MHz, CDCl3) δ 7.18 – 7.13 (m, 4H), 6.79 (s, 
1H), 6.59 (s, 1H), 5.90 (ddt, J = 17.2, 10.6, 5.8 Hz, 1H), 5.42 (d, J = 15.2 Hz, 1H), 5.33 (d, J 
= 17.2 Hz, 1H), 5.26 (d, J = 10.3 Hz, 1H), 4.97 (bs, 1H), 4.63 (d, J = 5.5 Hz, 2H), 4.44 (dd, J 
= 9.0, 2.5 Hz, 1H), 4.03 (s, 3H), 3.86 (s, 3H), 3.74 – 3.68 (m, 2H), 3.50 (d, J = 15.3 Hz, 1H), 
3.29 (d, J = 17.6 Hz, 1H), 2.76 (dd, J = 17.5, 9.2 Hz, 1H), 2.68 (s, 3H), 2.56 (s, 3H), 2.14 (s, 
3H), 1.43 (s, 9H). 







Cbz-Arg-Mtr-OH -CHA (cyclohexylamine salt) (0.595 g, 0.96 mmol, 1.2 eq.) was 
suspended in 40 mL of DCM. The organic phase was washed 3 times with KHSO4, dried 
over Na2SO4 and concentrated under reduced pressure to give Cbz-Arg-Mtr-OH free as 
a white foam (quantitative). The foam was dissolved in 7 mL of DMF under nitrogen 
atmosphere and cooled to 0°C, then HATU (0.380 g, 0.96 mmol, 1.2 eq.), HOAt (0.130 g, 
0.96 mmol, 1.2 eq.) and DIPEA (0.42 mL, 2.4 mmol, 3 eq.). The mixture was stirred at 0 
°C for 30 minutes.  
Boc-(3S,6R)-DKP-f3-COOAllyl 21 (0.523 g, 0,8 mmol, 1 eq.) was deprotected in a solution 
of 9 mL CH2Cl2/TFA 2:1 at room temperature. After 2 hours the solvent was evaporated, 
the excess of TFA was removed by adding toluene (2 × 5 mL) followed of evaporation. 
Diethyl ether (1 x 5) was also added and evaporated to afford the corresponding TFA 
salt, which was re-dissolved in DMF (9 mL) and DIPEA (0.13 mL, 0.8 mmol, 1 eq.) and 
incorporated to the reaction containing Cbz-Arg-Mtr-OH. The mixture was stirred for 1 
hour at 0°C and the at room temperature overnight.  
The mixture was then diluted in 150 mL of EtOAc. The organic phase was washed with 
KHSO4 1 M (3×45 mL), NaHCO3 sat (3×45 mL) and brine (1×50 mL), then dried over 
Na2SO4 and concentrated under reduced pressure. The residue was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH from 100% CH2Cl2 to 9:1) affording the 
product 22 as a white foam (0.730 g, 85% yield).  
Rf=0.5 (CH2Cl2/MeOH 9:1); 1H NMR (400 MHz, MeOD-d4) δ 7.40 – 7.25 (m, 5H), 7.13 
(dd, J = 34.5, 8.1 Hz, 4H), 6.67 (s, 1H), 6.64 (s, 1H), 5.95-5.85 (m, 1H), 5.35 – 5.28 (m, 
2H), 5.20 (dd, J = 10.5, 1.3 Hz, 1H), 5.08 (q, J = 12.5 Hz, 2H), 4.64 – 4.50 (m, 3H), 4.09 
(m, 1H),  4.05 – 3.98 (m, 3H), 3.90 – 3.83 (m, 4H), 3.81 (s, 3H), 3.77 – 3.74 (m, 1H), 3.59 
(dd, J = 13.8, 2.4 Hz, 1H), 3.21 (bs, 1H), 3.15 – 3.11 (m, 1H), 3.07 (dd, J = 17.7, 4.6 Hz, 
1H), 2.88 (dd, J = 17.6, 4.8 Hz, 1H), 2.66 (s, 3H), 2.60 (s, 6H), 2.48 (s, 3H), 2.11 (s, 3H), 
2.07 (s, 3H), 1.79 – 1.67 (m, 1H), 1.62 – 1.44 (m, 3H); 13C NMR (101 MHz, MeOD-d4) δ 
171.32, 168.73, 168.22, 160.68, 159.88, 158.44, 139.87, 139.52, 138.56, 137.89, 
135.98, 134.77, 133.47, 130.99, 129.52, 129.35, 129.21, 129.07, 128.92, 126.06, 
125.71, 118.56, 113.15, 112.79, 67.82, 66.50, 60.36, 56.16, 56.00, 51.94, 49.00, 47.70, 







Mtr-Arg-(3S,6R)-DKP-f3-COOAllyl 22 (0.537 g, 0.5 mmol, 1 eq.) was dissolved in 20 mL of 
dry DCM under nitrogen atmosphere at 0 °C. [Pd(PPh3)4] (cat.) and N-methylaniline 
(0.23 mL, 2 mmol, 4 eq.) were added, the reaction mixture was stirred 5 min at 0 °C and 
then 2 hours at room temperature. The mixture was diluted in 70 mL of DCM and 
washed with KHSO4 1 M (3×20 mL). The organic phase was dried over Na2SO4, volatiles 
were removed under reduced pressure and the residue was purified by flash 
chromatography DCM/MeOH from 98/2 to 8/2 affording 23 as a pale-yellow foam 
(0.373 g, 72%).  
Rf=0.2 (CH2Cl2/MeOH 95:5); 1H NMR (400 MHz, MeOD-d4) δ 7.36 – 7.20 (m, 5H), 7.13 – 
7.08 (m, 4H), 6.66 (s, 1H), 6.61 s, 1H), 5.24 (d, J = 15.2 Hz, 1H), 5.06 (m, 2H), 4.51 – 4.45 
(m, 3H), 4.10 (m, 1H), 4.04 – 3.98 (m, 3H), 3.91 – 3.82 (m, 4H), 3.81 – 3.73 (m, 4H), 3.53 
(d, J = 13.5 Hz, 1H), 3.26 – 3.07 (m, 2H), 2.96 (d, J = 14.1.7 Hz, 1H), 2.66 (s, 3H), 2.60 (s, 
6H), 2.47 (s, 3H), 2.09 (s, 3H), 2.07 (s, 3H), 1.77 – 1.67 (m, 1H), 1.62 – 1.40 (m, 3H); 13C 
NMR (101 MHz, MeOD-d4) δ 168.44, 160.37, 159.50, 157.95, 157.78, 139.68, 139.29, 
138.22, 137.54, 135.83, 134.39, 130.18, 129.28, 129.19, 128.85, 128.67, 125.95, 
125.59, 112.95, 112.58, 67.70, 56.08, 55.94, 54.16, 49.64, 49.43, 49.21, 49.00, 48.79, 
48.57, 48.36, 46.63, 24.54, 24.39, 18.81, 18.20, 12.15. 
(S)-tert-butyl 2-amino-4-((2-(benzyloxy)-2-oxo-ethyl)amino)-4-oxobutanoate 26 
 
To a solution of Fmoc-L-Asp(OH)-OtBu (1.15 g, 2.80 mmol, 1.2 eq.) in DMF (15 mL), at 0 
°C and under nitrogen atmosphere, HATU (1.06 g, 2.80 mmol, 1.2 eq.), HOAt (380 mg, 





was stirred at 0 °C for 30 min. A solution of H2N-Gly-OBn·HCl (465 mg, 2.3 mmol, 1 eq.) 
in 15 mL of DMF and DIPEA (1.2 mL, 6.9 mmol, 3 eq.) was added dropwise and the 
mixture was stirred at 0 °C for 1 h and at room temperature overnight. The mixture was 
diluted in500 mL of EtOAc and washed with KHSO4 1 M (3 × 100 mL), saturated aqueous 
NaHCO3 (3 × 100 mL) and brine (1 × 100 mL). The organic phase was dried over Na2SO4, 
concentrated under reduced pressure, and the residue was purified by flash 
chromatography on silica gel (CH2Cl2/MeOH from CH2Cl2 100% to 9:1, solid load) 
affording Fmoc-L.Asp-Gly-OBn as a white foam (0.985 g, 81%). The protected dipeptide 
(0.98 g, 1.8 mmol, 1 eq) in DMF (47 mL), at 0 °C under nitrogen atmosphere, piperidine 
(1.1.5 mL, 11.16 mmol, 5 eq) was added and the reaction mixture was stirred at 0 °C for 
10 min and at room temperature for 3 h. The mixture was diluted with AcOEt (400 mL) 
and washed with H2O (4×100 mL). The organic phase was dried over Na2SO4 and 
volatiles were removed under reduced pressure. The residue was purified by a Grace 
Reveleris system (column: Reveleris Silica 40 g; liquid load; flow rate: 33 mLmin-1; 
gradient: from DCM/MeOH 98/2 to 8/2 in 35 min) affording the desired product 41 as a 
white foam (600 mg, quant., 80% yield over 2 steps). 
Rf=0.35 (CH2Cl2/MeOH 95:5); 1H NMR (400 MHz, CDCl3) δ 7.99 (bs, J = 5.2 Hz, 1H), 7.29 
(m, 5H), 5.10 (s, 2H), 4.01 (m, J = 18.1, 5.2 Hz, 2H), 3.66 (m, J = 9.0, 3.2 Hz, 1H), 2.65 (dd, 
J = 15.4, 3.2 Hz, 1H), 2.44 (dd, J = 15.4, 9.0 Hz, 1H), 2.21 (bs, 2H), 1.40 (s, 9H). 
Mtr-Arg-(3S,6R)-DKP-f3-COO-isoAsp-Gly-OBn 27 
 
Mtr-Arg-(3S,6R)-DKP-f3-COOH 23 (0.509 g, 0.5 mmol, 1 eq.) was dissolved in 6 ml of 
DMF under nitrogen atmosphere and cooled to 0°C. HATU (0.228 g, 0.6 mmol, 1.2 eq.), 





the reaction mixture was stirred at 0 °C for 30 min. The dipeptide isoAsp-Gly 26 (0.202 
g, 0.6 mmol, 1.2 eq.), dissolved in 6 mL of DMF, was added and the mixture was stirred 
for 1 hour at 0 °C and then at room temperature overnight. The mixture was diluted in 
100 mL of CH2Cl2 and washed with KHSO4 1 M (3×40 mL), NaHCO3 (3×40 mL) and brine 
(1×25 mL). The organic phase was dried over Na2SO4, concentrated under reduced 
pressure and purified by flash chromatography DCM/MeOH from 100% DCM to 8/2 
affording the product 27 as a pale-yellow foam (0.560 g, 83%). 
Rf= 0.48 (CH2Cl2/MeOH  95:5); 1H NMR (400 MHz, Acetone) δ 7.83 (m, 1H), 7.71 (m, 
1H), 7.64 (d, J = 8.1 Hz, 1H), 7.51 (s, 1H), 7.38-7.29 (m, 10 H), 7.22-7.15 (dd, J = 18.4, 8.0 
Hz, 4H), 6.76 (s, 1H), 6.72 (t, J = 6.3 Hz, 1H), 6.66 (s, 1H), 6.58 (bs, 1H), 6.53 (d, J = 8.0 
Hz, 1H), 5.30 (d, J = 15.3 Hz, 1H), 5.14 (s, 2H), 5.11 – 5.02 (dd, J = 18.8, 12.8 Hz, 2H), 
4.75-4.70 (m, 1H), 4.64 (s, 1H), 4.28-4.23 (m, 1H), 4.05 (dd, J = 16.6, 10.7 Hz, 5H), 3.95 
(dd, J = 19.1, 5.7 Hz, 2H), 3.88 (s, 3H), 3.82 (s, 3H), 3.79 (m, 1H), 3.51-3.48 (d, J = 13.5 
Hz, 1H), 3.30 (bs, 1H), 3.16-3.07 (m, 2H), 3.03-3.02 (m, 1H), 2.80-2.73 (m, 3H), 2.67 (s, 
3H), 2.63 (s, 3H), 2.62 (s, 3H), 2.55 (s, 3H), 2.09 (m, 6H), 1.82 (m, 1H), 1.58 (m, 3H), 1.43 
(s, 9H); 13C NMR (101 MHz, Acetone) δ 174.10, 170.95, 170.89, 170.51, 167.33, 159.95, 
158.90, 157.57, 139.44, 139.28, 139.16, 138.17, 138.09, 137.07, 136.96, 136.33, 
129.34, 129.22, 129.02, 129.00, 128.76, 128.68, 128.65, 125.44, 124.83, 113.00, 
112.47, 82.20, 67.20, 67.17, 66.92, 60.03, 56.08, 55.85, 55.70, 55.34, 52.34, 50.81, 
47.27, 46.69, 41.78, 40.23, 39.75, 38.08, 30.42, 30.22, 30.03, 29.84, 29.65, 29.46, 29.26, 







Mtr-Arg-(3S,6R)-DKP-f3-COO-isoAsp-Gly-OBn 27 (0.765 g, 0.56 mmol,1eq.) was 
dissolved in 50 mL of a solution THF/water 1:1. A catalytic amount of Pd/C 10 % was 
added, and the mixture was purged under stirring with 3 cycles of vacuum/H2 
atmosphere. The reaction was stirred overnight under H2 atmosphere at room 
temperature. The mixture was filtered on a celite pad and rinsed with methanol. The 
filtrate was collected and concentrated under reduced pressure, affording the product 





Mtr-Arg-(3S,6R)-DKP-f3-COO-isoAsp-Gly 28 (200 mg, 0.17 mmol, 1 eq.) was dissolved in 
120 mL of DMF/CH2Cl2 1:1 (1.4 mM solution) under nitrogen atmosphere, the mixture 
was cooled to at 0 °C and HATU (266 mg, 0.7 mmol, 4 eq.), HOAt (95 mg, 0,7 mmol, 4 
eq.) and DIPEA (0.2 mL, 1.0 mmol, 6 eq.) were added.  the reaction was stirred at 0 °C 
for 1 hour and then at room temperature overnight. The mixture was concentrated 
under reduced pressure, the residue was diluted in 250 mL of EtOAc and washed with 
KHSO4 1 M (4 × 60 mL). The organic phase was dried over Na2SO4, concentrated under 
reduced pressure and the residue was purified by flash chromatography CH2Cl2/MeOH 
from 100% CH2Cl2 to 8/2 affording the product 29 as a pale-yellow solid (130 mg, 68%). 
Rf=0.4 (CH2Cl2/MeOH 9:1); 1H NMR (400 MHz, DMSO-d6) δ 8.59 (d, J = 9.0 Hz, 1H), 8.29 
(t, J = 6.2 Hz, 1H), 8.16 (d, J = 6.8 Hz, 1H), 7.87 (t, J = 6.0 Hz, 1H), 7.63 (dd, J = 6.8, 3.7 Hz, 





15.2, 7.1 Hz, 1H), 4.79 – 4.68 (m, 1H), 4.34 (d, J = 11.5 Hz, 1H), 4.16 (dd, J = 16.9, 7.3 Hz, 
1H), 4.04 (dd, J = 13.2, 7.3 Hz, 1H), 3.92-3.87 (m, 3H), 3.82 (s, 3H), 3.79 (s, 3H), 3.63 – 
3.57 (m, 2H), 3.49 (m, 3H), 3.03 (m, 3H), 2.60 – 2.51 (m, 11H), 2.44 (m, 3H), 2.12 (d, J = 
12.9 Hz, 1H), 2.05 (m, 6H), 1.65-1.52 (m, 1H), 1.45-1.39 (m, 12H) ; 13C NMR (101 MHz, 
DMSO) δ 172.75, 170.65, 169.75, 168.92, 168.66, 166.07, 165.86, 158.48, 157.47, 
156.21, 147.59, 139.35, 138.21, 137.79, 137.65, 137.23, 135.63, 135.22, 134.47, 
129.99, 127.89, 127.58, 124.03, 123.55, 119.11, 112.24, 111.73, 81.36, 55.66, 55.51, 




Cyclo[(3S,6R)-DKP-f3-isoDGR]-Mtr 29 (109 mg, 0.1 mmol) was treated with TFA (11 mL) 
in the presence of ion scavengers thioanisole (1.6 mL), ethanedithiol (0.8 mL) and 
phenol (175 mg). The mixture was cooled to 0 °C and flushed with N2, then 
trimethylsilylbromide (2.2 mL) was added and the flask was opened. The mixture was 
allowed to reach room temperature and stirred for 2 h. Volatiles were removed under 
reduced pressure and the crude was dissolved in 30 mL of a mixture of 
water/diisopropyl ether 1:1. The aqueous phase was washed several times with 
diisopropyl ether and then concentrated under reduced pressure to give the crude 
compound, which was purified by semipreparative HPLC (gradient: 97% H2O + 0.05% 
TFA/ 3% ACN + 0.05% TFA for 2 min, then to 80% H2O + 0.05% TFA / 20% ACN + 0.05% 
TFA in 9 min, tR product = 7 min) to afford the product 14 (50 mg, 58% yield). 
1H NMR (500 MHz, D2O) δ 7.49-7.39 (m, 4H), 5.30 (d, J = 15.7 Hz, 1H), 5.07 (dd, J = 11.5, 
3.8 Hz, 1H), 4.48 (dd, J = 11.6, 2.2 Hz, 1H), 4.33 – 4.22 (m, 3H), 4.21 (s, 2H), 4.18 (d, J = 





6.7 Hz, 2H), 3.18 (dd, J = 13.7, 2.7 Hz, 1H), 3.11 (dd, J = 15.2, 3.9 Hz, 1H), 2.79 (dd, J = 
15.1, 11.6 Hz, 1H), 2.46 – 2.38 (m, 1H), 1.93 – 1.82 (m, 1H), 1.77 – 1.63 (m, 2H); 13C 
NMR (101 MHz, D2O) δ 176.00, 174.05, 172.21, 172.10, 171.33, 167.85, 167.00, 156.78, 
136.11, 132.34, 129.38, 128.31, 128.16, 59.63, 54.17, 51.16, 49.10, 47.43, 42.70, 41.50, 
40.43, 39.26, 38.26, 37.38, 28.06, 24.49. MS (ESI) m/z calcd. for [C27H39N10O8]+: 631.29 
[M + H]+; found: 631.33. 
 
 
Synthesis of cyclo[DKP-isoDGR]-α-amanitin conjugates 31-33 
14-Azido-3,6,9,12-tetraoxatetradecanoic acid -NHS ester 40 
 
100 µL (0.05 mmol, 1 eq.) of a 0.5 M solution of 14-azido-3,6,9,12-
tetraoxatetradecanoic acid (0.5 M in tert-butyl methyl ether) were diluted in 100 µL of 
dry DCM under argon and cooled to 0 °C. EDC.HCl (12,5 mg, 0.065 mmol, 1.3 eq.) and 
NHS (7.5 mg, 0.065 mmol, 1.3 eq.) were sequentially added to the solution and the 
reaction mixture was stirred overnight at room temperature. The mixture was diluted in 
10 mL of DCM and the organic phase was washed with water (3 × 3 mL), dried over 
MgSO4, filtrated and concentrated under reduced pressure to give the product as a 
transparent oil (18.2 mg, 97% yield). The crude product was used in next step without 
further modifications. 
Rf= 0.35 (DCM/MeOH 95:5); 1H NMR (400 MHz, CDCl3): δ 4.52 (s, 2H), 3.81–3.79 (m, 
2H), 3.68-3.65 (m, 12H), 3.39 (t, J = 5.0 Hz, 2H), 2.85 (s, 4H). 






To a solution of compound 40 (9.2 mg, 24 µmol, 2 eq.) in 500 µL of ACN was added 
cyclo[DKP-isoDGR]-CH2NH2 14 (10.5 mg, 12 µmol, 1 eq.) dissolved in 500 µL of PBS pH 7. 
The pH was adjusted to 7.4 with a solution of NaOH 0.2 M and the reaction was stirred 
overnight at room temperature. The mixture was filtered into a 3 mL vial, centrifuged 
and purified by preparative HPLC (gradient: from 95% (H2O + 0.05 % CF3COOH)/5% 
CH3CN) to 60% (H2O + 0.05 % CF3COOH)/40% CH3CN in 14.5 mins, tR product = 8.3 min). 
The collected fraction was concentrated under reduced pressure and freeze-dried from 
1:1 water/CH3CN to afford the product as a white solid (5.5 mg, 46% yield).  
1H NMR (400 MHz, D2O) δ 7.34 (dd, J = 15.6, 8.4 Hz, 4H), 5.27 (d, J = 15.5 Hz, 1H), 5.08 
(dd, J = 11.5, 3.9 Hz, 1H), 4.50 – 4.43 (m, 3H), 4.32 – 4.17 (m, 3H), 4.15 (s, 2H), 4.12 (d, J 
= 4.1 Hz, 1H), 3.99 (dd, J = 14.8, 4.6 Hz, 1H), 3.83 (d, J = 17.2 Hz, 1H), 3.77 (m, 2H), 3.75 
– 3.70 (m, 3H), 3.69 – 3.58 (m, 10H), 3.47 – 3.42 (m, 2H), 3.19 (m, 3H), 3.09 (dd, J = 
15.1, 3.8 Hz, 1H), 2.78 (dd, J = 15.1, 11.6 Hz, 1H), 2.39 (dd, J = 13.4, 12.1 Hz, 1H), 1.89 – 
1.75 (m, 1H), 1.72 – 1.59 (m, 2H); 13C NMR (101 MHz, D2O) δ 175.93, 173.99, 172.70, 
172.19, 172.10, 171.27, 167.90, 166.91, 156.77, 137.64, 128.03, 127.79, 70.49, 70.12, 
69.63, 69.56, 69.53, 69.19, 67.63, 59.39, 54.11, 51.12, 50.14, 49.09, 47.34, 42.15, 41.51, 
40.42, 39.20, 38.14, 37.44, 28.04, 24.47. MS (ESI+): m/z calculated for [C37H56N13O13]+= 
890.41 [M + H]+, found: 890.96. 






α-amanitin 6’-aminohexyl ether 34 (11 mg, 10.9 µmol, 1 eq.) was dissolved in 150 µL of 
dry DMF under nitrogen atmosphere. The solution was cooled to 0 °C, then commercial 
di-N-succinimidyl glutarate (4 mg, 12 µmol. 1.1 eq.) and DIPEA (2 µL, 12 µmol, 1.1 eq.) 
were added and the mixture was stirred at room temperature for 6 hours. The reaction 
was monitored by TLC (CHCl3/MeOH/water 65/25/4, cinnamaldehyde staining). The 
crude was poured into 10 mL precooled MTBE placed in a 10 mL centrifugal tube (the 
reaction flask was rinsed with 3 × 50 µL of DMF and each rinsing solution was 
transferred to the MTBE tube). The tube was sealed, vortexed and placed in ice for 10 
min. The tube was spun for 3 min at 4500 RPM in a pre-cooled centrifuge. The 
supernatant was transferred to a 50 mL flask. The pellet was suspended again into 10 
mL of MTBE by vortexing and sonication. The tube was placed in ice for 10 mins and the 
centrifugation was repeated, then the pellet was dried in vacuo. The combined MTBE 
phases were concentrated under reduced pressure and checked for remaining product 
by TLC and HPLC. The dried pellet was used in next step without further purification (12 
mg, 90% yield).  
Cyclo[DKP-isoDGR]-uncleavable-α-amanitin 31 
 
A solution of cyclo[DKP-isoDGR]-CH2NH2 14 (5.0 mg, 5.8 µmol, 1 eq.) in 150 µL of PBS 
was added to a solution of 35 (12 mg, 10 µmol, 1.7 eq.) in 150 µL of DMF at 0 °C. The pH 
was adjusted to 7.3-7.6 by adding small aliquots of aqueous NaOH (0.2 M) during the 
first hours of reaction, until a stable value was observed, and then the reaction mixture 
was stirred overnight at room temperature.  
The solution was directly filtered into a 3 mL vial and purified by preparative HPLC 





CF3COOH)/40% CH3CN in 14.5 mins), tR (product): 8.8 min. The purified product was 
freeze-dried to give the final product as a white solid (4.5 mg, 45% yield). MS (ESI+): m/z 
calcd. for [C77H110N21O24S]+ = 1744.77 [M + H]+, found: 1745,67. 
Glutarate NHS ester-Val-Ala- α-amanitin 37 
 
Val-Ala-PAB-α-amanitin 36 (10 mg, 8.3 µmol, 1 eq.) was dissolved in 150 µL of dry DMF 
under nitrogen atmosphere. The solution was cooled to 0 °C, then commercial di-N-
succinimidyl glutarate (3.2 mg, 9.9 µmol, 1.2 eq.) and DIPEA (1.6 µL, 9.1 µmol, 1.1 eq.) 
were added and the mixture was stirred at room temperature for 6 hours. The reaction 
was monitored by TLC (CHCl3/MeOH/water 65/25/4, cinnamaldehyde staining). The 
crude was poured into 10 mL pre-cooled MTBE placed in a 10 mL centrifugal tube (the 
reaction flask was rinsed with 3 × 50 µL of DMF and each rinsing solution was 
transferred to the MTBE tube).  The tube was sealed, vortexed and placed in ice for 10 
mins. The tube was spun for 3 mins at 4500 RPM in a precooled centrifuge. The 
supernatant was transferred to a 50 mL flask. The pellet was suspended again into 10 
mL of MTBE by vortexing and sonication. The tube was placed on ice for 10 mins and 
the centrifugation was repeated. Then the pellet was dried in vacuo. The combined 
MTBE phases were concentrated under reduced pressure and checked for remaining 
product by TLC and HPLC. The dried pellet was used in next step without further 







A solution of cyclo[DKP-isoDGR]-CH2NH2 14 (3.4 mg, 3.9 µmol, 1 eq.) in 150 µL of PBS 
was added to a solution of 37 (8.3 mg, 5.9 µmol, 1.5 eq.) in 150 µL of DMF at 0 °C. The 
pH was adjusted to 7.3-7.6 by adding small aliquots of aqueous NaOH (0.2 M) during the 
first hours of reaction (until a stable value was observed), then the reaction mixture was 
stirred overnight at room temperature. The solution was directly filtered into a 3 mL vial 
and purified by preparative HPLC (gradient: from 95% (H2O + 0.05 % CF3COOH)/5% 
CH3CN to 60% (H2O + 0.05 % CF3COOH)/40% CH3CN in 14.5 mins), tR (product): 9.2 min. 
The purified product was freeze-dried to give the final product as a white solid (4.8 mg, 
62% yield). MS (ESI+): m/z calculated for [C86H118N23O26S]+= 1921.05 [M + H]+, found: 
1921.75. 
4-Pentynoic acid NHS ester 39 
 
4-Pentynoic acid (10 mg, 0.100 mmol, 1 eq.) was dissolved in 2 mL of dry DCM under 
argon and cooled to 0 °C. EDC.HCl (23 mg, 0.120 mmol, 1.2 eq.) and NHS (14 mg, 0.120 
mmol, 1.2 eq.) were sequentially added to the solution and the reaction mixture was 
stirred overnight at room temperature. The mixture was diluted in 20 mL of DCM and 
the organic phase was washed with water (3 × 7 mL), dried over MgSO4, filtrated and 
concentrated under reduced pressure to give the product as a yellowish oil that was 
used in next step without further modifications. 






Under argon, DIPEA (1 µL, 6.3 µmol, 1.5 eq.) and compound 39 dissolved in DCM (200 
µL) were added to a solution of compound 36 (5.0 mg, 4.2 µmol, 1 eq.) in 200 µL of 
DMF kept at 0 °C. The reaction mixture was stirred overnight at room temperature. 
Volatiles were evaporated under reduced pressure and the crude was dissolved in 500 
µL of MeOH and then purified by preparative HPLC (gradient: from 95% (H2O + 0.05% 
CF3COOH) / 5% (CH3CN) to 0% (H2O + 0.05% CF3COOH)/100% (CH3CN) in 15 mins), tR 
product = 7.97 min. The collected fraction was concentrated under reduced pressure 
and freeze-dried from water/ACN 1/1 to afford the product as a white solid (4.7 mg, 
88% yield). MS (ESI+): m/z calculated for [C59H80N13O17S]+ = 1273.54 [M + H]+, found: 
1274.55. 
Cyclo[DKP-isoDGR]-PEG-4-Val-Ala- α-amanitin 33 
 
To a solution of 39 (2.9 mg, 2.3 µmol) in 1 mL of DMF at 0 °C, compound 41 (2.7 mg, 2,7 
µmol) dissolved 1 mL of water, sodium ascorbate (0.2 mg, 0.88 µmol) and CuSO4·5 H2O 
(0.07 mg, 0.44 µmol) were sequentially added. The solution, which turned light yellow, 
was stirred overnight at room temperature until the color changed to light blue. 
Volatiles were evaporated under reduced pressure and the crude was re-dissolved in 
400 µL of MeOH, filtered and purified by preparative HPLC (gradient: from 95% (H2O + 





(CH3CN + 0.05% CF3COOH) in 15 min, tR product = 7.2 min). The collected fraction was 
concentrated under reduced pressure and freeze-dried from 1:1 water/CH3CN to afford 
the product as a white solid (3.33 mg, 62% yield). MS (ESI+): m/z calculated for 
[C96H136N26O30S2]2+= 1082.48 [M + 2H]2+, found: 1082.92. 
 
Synthesis of cyclo[DKP-isoDGR]-MMAE/MMAF conjugates 46-49 
14-Hydroxy-3,6,9,12-tetraoxatetradecyl-4'-methylbenzolsulfonate 50-a  
 
PEG-4 (8.7 mL, 50 mmol, 5 eq.) was dissolved in 2.5 mL of THF. Sodium hydroxide (640 
mg, 16 mmol, 1.6 eq.) in 2.5 mL of H2O was added and the mixture was cooled down to 
0 °C. A solution of p-toluenesulfonyl chloride (1.9 g, 10 mmol, 1 eq.) in 7.5 mL of THF 
was slowly added and the mixture was stirred for 2 hours at 0 °C. The mixture was 
poured into water (40 mL), and the layers were separated. The aqueous phase was 
extracted with DCM (4 × 15 mL) and the combined organic phases were washed with 
water (3 × 15 mL), dried over Na2SO4 and concentrated under reduced pressure to yield 
the product as a colorless oil (3.33 g, 96% yield) which was used in the next step 
without further purification. 
Rf= 0.7 (DCM/MeOH 95:5); 1H NMR (400 MHz, CDCl3): δ 7.79–7.77 (d, J = 8.0 Hz, 2H), 
7.34-7.32 (d, J = 7.9, 1.0 Hz, 2H), 4.16–4.13 (m, 2H), 3.73–3.55 (m, 14H), 2.43 (s, 4H). 
2-(2-(2-(2-Azidoethoxy) ethoxy) ethoxy) ethan-1-ol 50-b  
 
To a solution of 50-a (3.18 g, 9.1mmol, 1 eq.) in 25 mL of ACN, was added sodium azide 
(0.975 g, 15 mmol, 1.6 eq.) and the mixture was heated to reflux with stirring for 8 h. 
The solution was allowed to cool down to room temperature then diluted in 25 mL of 
water and the aqueous phase was extracted with DCM (3 × 25 mL). The combined 





pressure to give the product as a pale-yellow oil. The crude product was purified by 
flash chromatography on silica gel (CH2Cl2/MeOH from 100% CH2Cl2 to 95:5) affording 
the desired product 50-b as a pale-yellow oil (1.46 g, 70% yield).  
Rf= 0.6 (DCM/MeOH 95:5); 1H NMR (400 MHz, CDCl3): δ 3.73–3.60 (m, 14H), 3.40 (m, 
2H), 2.18 (s, 1H).  
14-Azido-3,6,9,12-tetraoxatetradecanoic acid 51  
 
A solution of 50-b (100 mg, 0.4 mmol, 1 eq.) in 2.5 mL of dry THF was added dropwise 
to a stirred suspension of NaH (67 mg, 2.8 mmol, 7 eq.) in 2.5 mL of dry THF under N2 at 
0°C. The mixture was stirred for 1 h at room temperature. A solution of bromoacetic 
acid (111 mg, 0.8 mmol, 2 eq.) in 50 mL of dry THF was added dropwise and the mixture 
was stirred overnight at room temperature. Once the reaction was completed, the 
excess of NaH was quenched by carefully adding cold water and the solvent was 
evaporated under reduced pressure. The remaining aqueous solution was diluted in 5 
mL of water, acidified with HCI 1 M solution until pH < 5 and extracted with DCM (3 x 10 
mL). The organic extracts were combined, washed with water, dried over Na2SO4 and 
evaporated under reduced pressure, affording a dense oil. The crude residue was 
purified by flash chromatography on silica gel (CH2Cl2/MeOH from 100% CH2Cl2 to 8:2) 
to afford the product as a colorless oil (81 mg, 73%, yield). 
Rf= 0.15 (DCM/MeOH 9:1); 1H NMR (400 MHz, CDCl3): δ 4.16 (s, 2H), 3.78–3.76 (m, 2H), 
3.71-3.65 (m, 12H), 3.40 (t, J = 5.0 Hz, 2H). 
Fmoc-Val-Ala-OH 52 
 
Fmoc-Val-OH (1.5 g, 4.4 mmol, 1 eq.) and NHS (0.560 g, 4.8 mmol, 1.1 eq.) were 
dissolved in 16 ml of dry THF under N2. The solution was cooled to 0° C to add DCC 





temperature. The suspension was filtered over cotton to separate the N,N'-
dicyclohexylurea and the filtrate was concentrated under reduced pressure to afford 
the Fmoc-Val-O-succinimide as a white foam.  
The activated amino acid was suspended in a mixture of THF/diethyl ether 1:1 and an 
aqueous solution of alanine (0.428 g, 4.8 mmol, 1.1 eq.) and NaHCO3 (0.403 g, 4.8 
mmol, 1.1 eq.) dissolved in 15 mL of water was added. The suspension was diluted with 
THF (5 mL approx..) till obtaining a clear solution that was stirred at room temperature 
for 4 days. The solvents were removed under reduced pressure, the residue was diluted 
in 30 mL of citric acid (15% w/v) and 50 mL ethyl acetate, and the mixture was stirred 
one hour at room temperature. The aqueous phase was extracted with EtOAc (3 x 30 
mL), the combined organic phases were dried over Na2SO4 and concentrated under 
reduced pressure to give the crude product, that was purified by flash chromatography 
on silica gel (CH2Cl2/MeOH from 100% CH2Cl2 to 9:1 + 0.1% acetic acid) to afford the 
product as a white solid (1.3 g, 74%, yield). 
Rf= 0.45 (DCM/MeOH 10:1); 1H NMR (DMSO-d6): δ 12.44 (bs., 1H), 8.20 (d, 1H, J = 6.7 
Hz), 7.89 (d, 2H, J = 7.5 Hz), 7.75 (t, 2H, J = 6.5 Hz), 7.43-7.38 (m, 3H), 7.36-7.30 (m, 2H), 
4.31-4.17 (m, 4H), 3.90 (t, 1H, J = 7.2 Hz), 2.0-1.95 (m, 1H), 1.27 (d, 3H, J = 7.3 Hz), 0.90 
(d, 3H, J = 6.8 Hz), 0.87 (d, 3H, J = 6.8 Hz).  
Fmoc-Val-Ala-PABOH 53 
 
Fmoc-Val-Ala-OH 52 (180 mg, 0.43 mmol, 1 eq.), 4-aminobenzyl alcohol (65 mg, 0.52 
mmol, 1.2 eq.) and EEDQ (165 mg, 0.64 mmol, 1.5 eq.) were suspended in 30 mL of dry 
DCM under nitrogen atmosphere. The mixture was treated with methanol (12 mL 
approx.) until a clear solution resulted and was stirred for 48 hours at room 
temperature. Once the reaction was completed, volatiles were evaporated at 
rotavapor, 10 mL of diethyl ether were added, and the mixture was sonicated for 15 





filtered under reduce pressure. This operation was repeated twice, obtaining the Fmoc-
Val-Ala-PABOH 53 as pale-yellow solid (129 mg, 58%). 
1H NMR (DMSO-d6): δ 9.91 (bs., 1H), 8.16 (d, 1H, J = 6.8 Hz), 7.90 (d, 2H, J = 7.2 Hz), 7.74 
(m, 2H), 7.54 (d, 2H, J = 8.1 Hz), 7.47-7.40 (m, 3H), 7.32 (m, 2H), 7.24 (d, 2H, J = 8.0 Hz), 
5.08 (s, 1H), 4.43-4.40 (s, 3H), 4.30-4.22 (m, 3H) 3.91 (t, 1H, J = 7.6 Hz), 2.0-1.98 (m, 1H), 
1.31 (d, 3H, J = 6.5 Hz), 0.90 (m, 6H).  
Fmoc-Val-Ala-PAB-PNP 54 
 
Fmoc-Val-Ala-PABOH 53 (166 mg, 0.32 mmol, 1eq.) was dissolved in 5 mL of dry THF 
under N2, pyridine (64 µL, 0.8 mmol, 2.5 eq.) was added and the solution was cooled 
down to 0°C. 4-nitrophenyl chloroformate (97 mg, 0.48 mmol, 1.5 eq.) was added to the 
reaction and it was stirred at room temperature for 4 hours. The mixture was diluted in 
35 mL of EtOAc and washed with KHSO4 1M (2 x 7 mL) and brine (2 x 7 mL), then the 
organic phase was dried over Na2SO4 and concentrated under reduced pressure. The 
crude residue was purified by flash chromatography on silica gel (Hexane/EtOAc from 
5:5 to 20% hexane/80% EtOAc) affording the product as a white solid (135 mg, 62%, 
yield). 
1H NMR (DMSO-d6): δ 10.07 (s, 1H), 8.32-8.30 (d, J = 9.0 Hz, 2H), 8.20-8.18 (d, J = 6.8 Hz, 
1H), 7.90-7.88 (d, J = 7.5 Hz, 2H), 7.76-7.72 (t, J = 6.8 Hz, 2H), 7.65-7.62 (d, J = 8.3 Hz, 
2H), 7.58-7.56 (d, J = 9.0 Hz, 2H),  7.42-7.40 (m, 5H), 7.34-7.30 (t, J = 7.2 Hz, 2H), 5.24 (s, 
2H), 4.43 (m, 1H), 4.30-4.22 (m, 3H), 3.92 (t, 1H, J = 7.6 Hz), 2.0-1.97 (m, 1H), 1.32 (d, J = 







Monomethyl auristatin E (10 mg, 14 µmol, 1 eq.) was dissolved in dry DMF (300 μL) 
under nitrogen atmosphere. Fmoc-Val-Ala-PAB-PNP 54 (10 mg, 14 µmol, 1 eq.), HOAt (1 
mg, 7 µmol, 0.5 eq.) and DIPEA (12 μL, 70 µmol, 5.0 eq.) were added subsequently and 
the mixture was stirred at room temperature overnight. Piperidine (8 µL, 70 µmol, 5 
eq.) was added to the reaction and this was stirred for 2 additional hours at room 
temperature. The mixture was then diluted with 5mL of EtOAc, the organic phase was 
washed with NaHCO3 sat (3 x 1 mL), dried and concentrated under reduced pressure. 
The crude product was purified by semipreparative HPLC (gradient: from 95% (H2O + 
0.1% CF3COOH) / 5% (CH3CN + 0.1% CF3COOH) to 20% (H2O + 0.1% CF3COOH) / 80% 
(CH3CN + 0.1% CF3COOH) in 17 min, tR product = 11 min). The collected fractions were 
concentrated under reduced pressure and freeze-dried from 1:1 water/CH3CN to afford 
the product as a white solid (9.3 mg, 64% yield). MS (ESI+): m/z calculated for 
[C55H89N8O11]+= 1038.66 [M + H]+, found: 1038.65. 
Val-Ala-PABC-MMAF 56 
 
Monomethyl auristatin F (10 mg, 13.6 µmol, 1 eq.) was dissolved in dry DMF (100 μL) 
under nitrogen atmosphere. Fmoc-Val-Ala-PAB-PNP 54 (11 mg, 16.3 µmol, 1.2 eq.), 
HOAt (2 mg, 7 µmol, 0.5 eq.) and DIPEA (12 μL, 68 µmol, 5.0 eq.) were added 
subsequently and the mixture was stirred at room temperature overnight. Piperidine (7 
µL, 68 µmol, 5 eq.) was added to the reaction and the mixture was stirred for 2 hours at 
room temperature. The solvent was removed reduced pressure and the crude product 
was purified by semipreparative HPLC (gradient: from 95% (H2O + 0.1% CF3COOH) / 5% 
(CH3CN + 0.1% CF3COOH) to 20% (H2O + 0.1% CF3COOH) / 80% (CH3CN + 0.1% 
CF3COOH) in 17 min, tR product = 12 min). The collected fractions were concentrated 
under reduced pressure and freeze-dried from 1:1 water/CH3CN to afford the product 
as a white solid (8.8 mg, 62% yield). MS (ESI+): m/z calculated for [C55H87N8O12]+= 
1052.65 [M + H]+, found: 1052.38. 






Val-Ala-PABC-MMAE 55 (9.3 mg, 9 µmol, 1 eq.) was dissolved in 100 µL of dry DMF 
under nitrogen atmosphere. 4-pentynoic acid-NHS ester 39 (4 mg, 18 µmol, 2 eq.) in 
100 µL of dry DMF, and DIPEA (3 µL, 18 µmol, 2 eq.) were added and the mixture was 
stirred overnight at room temperature. The solvent was removed under reduced 
pressure and the crude residue was purified by semipreparative HPLC (gradient: from 
95% (H2O + 0.1% CF3COOH) / 5% (CH3CN + 0.1% CF3COOH) to 20% (H2O + 0.1% 
CF3COOH) / 80% (CH3CN + 0.1% CF3COOH) in 17 min, tR product = 14 min). The 
collected fractions were concentrated under reduced pressure and freeze-dried from 
1:1 water/CH3CN to afford the product as a white solid (7.5 mg, 75% yield). MS (ESI+): 




4-pentynoic acid-Val-Ala-PABC-MMAF 58 
 
Val-Ala-PABC-MMAF 56 (8.8 mg, 8 µmol, 1 eq.) was dissolved in 100 µL of dry DMF 
under nitrogen atmosphere. 4-pentynoic acid-NHS ester 39 (3 mg, 16 µmol, 2 eq.) in 
100 µL of dry DMF, and DIPEA (3 µL, 16 µmol, 2 eq.) were added and the mixture was 
stirred overnight at room temperature. The solvent was removed under reduced 
pressure and the crude residue was purified by semipreparative HPLC (gradient: from 
95% (H2O + 0.1% CF3COOH) / 5% (CH3CN + 0.1% CF3COOH) to 20% (H2O + 0.1% 
CF3COOH) / 80% (CH3CN + 0.1% CF3COOH) in 17 min, tR product = 14 min). The 





1:1 water/CH3CN to afford the product as a white solid (5.6 mg, 62% yield). MS (ESI-): 
m/z calculated for [C60H89N8O13]-= 1130.66 [M - H]-, found: 1130.37. 
Cyclo[DKP-isoDGR]-PEG-4-Val-Ala-PABC-MMAE 46 
 
4-pentynoic acid-Val-Ala-PABC-MMAE 57 (3 mg, 2.7 µmol, 1 eq.) was dissolved in 500 µL 
of dry DMF and added to a solution of cyclo[DKP-isoDGR]-PEG-4 41 (4 mg, 4 µmol, 1.5 
eq.) in 500 µL of degassed water, under nitrogen atmosphere. Sodium ascorbate (0.3 
mg, 1.4 µmol, 0.5 eq.) and CuSO4.5H2O (0.2 mg, 0.8 µmol, 0.3 eq.) were added to the 
solution and the mixture was stirred overnight at room temperature. Volatiles were 
removed under reduced pressure and the residue was purified by semipreparative HPLC 
(gradient: from 95% (H2O + 0.1% CF3COOH) / 5% (CH3CN + 0.1% CF3COOH) to 20% (H2O 
+ 0.1% CF3COOH) / 80% (CH3CN + 0.1% CF3COOH) in 17 min, tR product = 11.3 min). The 
collected fractions were concentrated under reduced pressure and freeze-dried from 
1:1 water/CH3CN to afford the product as a white solid (4.2 mg, 66% yield). MS (ESI+): 
m/z calculated for [C97H149N21O25]2+ = 1005.17 [M + 2H]2+, found: 1005.08.  
Cyclo[DKP-isoDGR]-PEG-4-Val-Ala-PABC-MMAF 47 
 
4-pentynoic acid-Val-Ala-PABC-MMAF 58 (3.5 mg, 3 µmol, 1 eq.) was dissolved in 500 µL 
of dry DMF and added to a solution of cyclo[DKP-isoDGR]-PEG-4 41 (4.5 mg, 4.5 µmol, 





(0.3 mg, 1.5 µmol, 0.5 eq.) and CuSO4.5H2O (0.3 mg, 1 µmol, 0.3 eq.) were added to the 
solution and the mixture was stirred overnight at room temperature. Volatiles were 
removed under reduced pressure and the residue was purified by semipreparative HPLC 
(gradient: from 95% (H2O + 0.1% CF3COOH) / 5% (CH3CN + 0.1% CF3COOH) to 20% (H2O 
+ 0.1% CF3COOH) / 80% (CH3CN + 0.1% CF3COOH) in 17 min, tR product = 11.5 min). The 
collected fractions were concentrated under reduced pressure and freeze-dried from 
1:1 water/CH3CN to afford the product as a white solid (2.8 mg, 45% yield). MS (ESI+): 
m/z calculated for [C97H147N21O26]2+ = 1011.54 [M + 2H]2+, found: 1011.96  
4-pentynoic acid-MMAE 59 
 
MMAE (7 mg, 9.7 µmol, 1 eq.) was dissolved in 100 µL of dry DMF. 4-pentynoic acid-
NHS ester 39 (3 mg, 15 µmol, 1.5 eq.) in 100 µL of dry DMF, and DIPEA (3 µL, 15 µmol, 
1.5 eq.) were added and the mixture was stirred overnight at room temperature. The 
solvent was removed under reduced pressure and the residue was purified by 
semipreparative HPLC (gradient: from 95% (H2O + 0.1% CF3COOH) / 5% (CH3CN + 0.1% 
CF3COOH) to 20% (H2O + 0.1% CF3COOH) / 80% (CH3CN + 0.1% CF3COOH) in 17 min, tR 
product = 14 min). The collected fractions were concentrated under reduced pressure 
and freeze-dried from 1:1 water/CH3CN to afford the product as a white solid (5.5 mg, 
73% yield). MS (ESI+): m/z calculated for [C44H72N5O8]+= 799.54 [M + H]+, found: 799.23. 
4-pentynoic acid-MMAF 60 
 
MMAF (6 mg, 8 µmol, 1 eq.) was dissolved in 100 µL of dry DMF. 4-pentynoic acid-NHS 
ester 39 (2.5 mg, 12 µmol, 1.5 eq.) in 100 µL of dry DMF, and DIPEA (3 µL, 12 µmol, 1.5 





solvent was removed under reduced pressure and the residue was purified by 
semipreparative HPLC (gradient: from 95% (H2O + 0.1% CF3COOH) / 5% (CH3CN + 0.1% 
CF3COOH) to 20% (H2O + 0.1% CF3COOH) / 80% (CH3CN + 0.1% CF3COOH) in 17 min, tR 
product = 13.8 min). The collected fractions were concentrated under reduced pressure 
and freeze-dried from 1:1 water/CH3CN to afford the product as a white solid (5.5 mg, 
73% yield). MS (ESI+): m/z calculated for [C44H70N5O9]+= 813.52 [M + H]+, found: 813.11. 
Cyclo[DKP-isoDGR]-PEG-4-MMAE 48 
 
4-pentynoic acid-MMAE 59 (3 mg, 3.8 µmol, 1 eq.) was dissolved in 500 µL of dry DMF 
and added to a solution of cyclo[DKP-isoDGR]-PEG-4 41 (6 mg, 6 µmol, 1.5 eq.) in 500 µL 
of degassed water, under nitrogen atmosphere. Sodium ascorbate (0.4 mg, 2 µmol, 0.5 
eq.) and CuSO4.5H2O (0.3 mg, 1.2 µmol, 0.3 eq.) were added to the solution and the 
mixture was stirred overnight at room temperature. Volatiles were removed under 
reduced pressure and the residue was purified by semipreparative HPLC (gradient: from 
95% (H2O + 0.1% CF3COOH) / 5% (CH3CN + 0.1% CF3COOH) to 20% (H2O + 0.1% 
CF3COOH) / 80% (CH3CN + 0.1% CF3COOH) in 17 min, tR product = 9.7 min). The 
collected fractions were concentrated under reduced pressure and freeze-dried from 
1:1 water/CH3CN to afford the product as a white solid (4.2 mg, 66% yield). MS (ESI+): 







4-pentynoic acid-MMAF 60 (4.5 mg, 5.5 µmol, 1 eq.) was dissolved in 500 µL of dry DMF 
and added to a solution of cyclo[DKP-isoDGR]-PEG-4 41 (8 mg, 8 µmol, 1.5 eq.) in 500 µL 
of degassed water, under nitrogen atmosphere. Sodium ascorbate (0.6 mg, 2.8 µmol, 
0.5 eq.) and CuSO4.5H2O (0.4 mg, 1.2 µmol, 0.3 eq.) were added to the solution and the 
mixture was stirred overnight at room temperature. Volatiles were removed under 
reduced pressure and the residue was purified by semipreparative HPLC (gradient: from 
95% (H2O + 0.1% CF3COOH) / 5% (CH3CN + 0.1% CF3COOH) to 20% (H2O + 0.1% 
CF3COOH) / 80% (CH3CN + 0.1% CF3COOH) in 17 min, tR product = 10.2 min). The 
collected fractions were concentrated under reduced pressure and freeze-dried from 
1:1 water/CH3CN to afford the product as a white solid (4.2 mg, 66% yield). MS (ESI+): 




HPLC traces of the final compounds 
Cyclo[DKP-isoDGR]-uncleavable-α-amanitin 31 
Phenomenex Luna C-18(2) column 10 µm, 250 × 21.2 mm, with precolumn at 30 
mL/min flow rate; gradient: 95% (H2O + 0.05 % CF3COOH)/5% CH3CN to 60% (H2O + 








Phenomenex Luna C-18(2) column 10 µm, 250 × 21.2 mm, with precolumn at 30 
mL/min flow rate; gradient: 95% (H2O + 0.05 % CF3COOH)/5% CH3CN to 60% (H2O + 
0.05 % CF3COOH)/40% CH3CN in 14.5 mins, tR product: 9.2 min 
Purity: 100%. 
 
Cyclo[DKP-isoDGR]-PEG-4-Val-Ala- α-amanitin 33 
Phenomenex Luna C-18(2) column 10 µm, 250 × 21.2 mm, with precolumn at 30 
mL/min flow rate; gradient: 95% (H2O + 0.05 % CF3COOH)/5% CH3CN to 100% CH3CN in 




Waters Atlantis 21 mm × 10 cm column; flow: 15 mL/min, gradient: 95% (H2O + 0.1% 
CF3COOH) / 5% (CH3CN + 0.1% CF3COOH) to 20% (H2O + 0.1% CF3COOH) / 80% (CH3CN + 








Waters Atlantis 21 mm × 10 cm column; flow: 15 mL/min, gradient: 95% (H2O + 0.1% 
CF3COOH) / 5% (CH3CN + 0.1% CF3COOH) to 20% (H2O + 0.1% CF3COOH) / 80% (CH3CN + 




Waters Atlantis 21 mm × 10 cm column; flow: 15 mL/min, gradient: 95% (H2O + 0.1% 
CF3COOH) / 5% (CH3CN + 0.1% CF3COOH) to 20% (H2O + 0.1% CF3COOH) / 80% (CH3CN + 




Waters Atlantis 21 mm × 10 cm column; flow: 15 mL/min, gradient: 95% (H2O + 0.1% 
CF3COOH) / 5% (CH3CN + 0.1% CF3COOH) to 20% (H2O + 0.1% CF3COOH) / 80% (CH3CN + 














































































4-pentynoic acid-MMAE 59 
 

















Appendix of NMR data  
 
4-((4-methoxy-2,3,6-trimethylphenylsulfonyl)aminomethyl)benzaldehyde 16 

































1H NMR (400 MHz, CDCl3) 
 
N3-(3S-6R)-DKP-f3-COOAllyl 20 
























1H NMR (400 MHz, MeOD-d4) 
 









1H NMR (400 MHz, MeOD-d4) 
 
 







(S)-tert-butyl 2-amino-4-((2-(benzyloxy)-2-oxo-ethyl)amino)-4-oxobutanoate 26 

















1H NMR (400 MHz, acetone) 
 








13C NMR (400 MHz, DMSO-d6) 
 








1H NMR (400 MHz, D2O) 
 








14-Hydroxy-3,6,9,12-tetraoxatetradecyl-4'-methylbenzolsulfonate 50-a  
1H NMR (400 MHz, CDCl3) 
 
2-(2-(2-(2-Azidoethoxy) ethoxy) ethoxy) ethan-1-ol 50-b  






14-Azido-3,6,9,12-tetraoxatetradecanoic acid 51  
1H NMR (400 MHz, CDCl3) 
 
14-Azido-3,6,9,12-tetraoxatetradecanoic acid -NHS ester 40 






N3-PEG-4-cyclo[DKP- isoDGR] 41 
1H NMR (400 MHz, D2O) 
 








1H NMR (400 MHz, DMSO-d6) 
 
Fmoc-Val-Ala-PABOH 53 
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Synthesis of novel conjugates based on a functionalized 
cyclo[DKP-isoDGR] integrin ligand and potent cytotoxic agents 
Abstract: Targeted drug delivery is a growing-interest field in cancer therapy as 
a strategy for overcoming the systemic cytotoxicity associated to traditional 
chemotherapy. One important approach in this research area is represented by 
the small molecule-drug conjugates (SMDCs), where the drug-targeting is 
performed by a low molecular weight ligand (peptide, vitamin or peptidomimetic) 
connected to a potent warhead through a stable linker. This PhD thesis 
describes the synthesis and biological evaluation of novel SMDCs containing 
the functionalized cyclo[DKP-isoDGR] integrin ligand developed by our research 
group and potent cytotoxic drugs (α-amanitin, MMAE and MMAF) combined via 
different linkers and spacers. The conjugates were evaluated for their binding 
affinity to the isolated αvβ3 receptor and for their antiproliferative activity on 
cancer cell lines with different levels of αVβ3 expression in order to study the 
efficacy of the cyclo[DKP-isoDGR] integrin ligand as a vector for tumor drug-
delivery. 
Keywords: cancer, drug delivery, integrins, peptidomimetics, isoDGR, SMDC 
 
 
 
 
 
